Roche

Q1 2015 sales

Basel, 22 April 2015 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com All mentioned trademarks are legally protected. 3 Group Severin Schwan Chief Executive Officer

4 Q1 2015: Highlights

Growth

• Group sales +5%1 driven by HER2 franchise (+23%1), Avastin (+6%1), Actemra (+27%1) and Professional Diagnostics (+6%1) • Esbriet: Off to a strong start

Innovation

• Second Breakthrough Therapy Designation for anti-PDL1 • Phase 3 starts: Seven in immuno-oncology, etrolizumab in Crohn’s disease and taselisib in HR+ breast cancer

M&A

• Foundation Medicine: Transaction closed

1 CER=Constant Exchange Rates 5 Q1 2015: Strong sales growth

2015 2014 Change in % CHFbn CHFbn CHF CER Pharmaceuticals Division 9.3 9.0 3 4

Diagnostics Division 2.5 2.5 2 6

Roche Group 11.8 11.5 3 5

CER=Constant Exchange Rates 6 Q1 2015: Continued strong growth in all regions

CHFbn 6 +6% 5 +3%

4 +1% +10% 3 Diagnostics +3% +14% +6% Pharma 2 -3% * +1% 1 -10% +9% -2% 0 Japan International Europe US

* Japanese sales impacted by consumption tax base effect

CER=Constant Exchange Rates 7 Q1 2015: Sales growth for 5th consecutive year

10%

8% 8% 7% 6% 6% 6% 6% 6% 5% 5% 4% 5% 4% 4% 4% 4%

2% 2% 0% 0% 1% 0% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 11 11 11 11 12 12 12 12 13 13 13 13 14 14 14 14 15

All growth rates at Constant Exchange Rates (CER) 8 Progressing in Personalised Healthcare 60% of phase 2 & 3 products have PHC component

Phase 2 Phase 3/Registration Marketed

FIXa /FX bispecific MAb MAO-B inh PD-L1 MAb Tarceva® SERD GABRA5 NAM venetoclax (Bcl-2 inh) Zelboraf®

CSF-1R MAb bitopertin alectinib (ALK inh) Erivedge® Ang2 -VEGF MAb basimglurant taselisib Rituxan® ipatasertib V1 receptor antag cobimetinib Gazyva®

crenezumab lebrikizumab Herceptin® olesoxime etrolizumab Perjeta® gantenerumab glypican-3 MAb Kadcyla®

Flu A MAb ocrelizumab Avastin® LptD antibiotic lampalizumab Xeloda® Esbriet®

Pulmozyme® Oncology Molecular Diagnostics Xolair® Immunology Tissue Diagnostics Infectious Diseases Actemra® Professional Diagnostics Neuroscience Lucentis® Ophthalmology 9 Roche: Making progress in advancing patient care Recognising innovation 2012-15

Breakthrough Therapy 6 Designations

Rank Company # Q1 2015 Anti-PDL1 (NSCLC) 1 Roche 6 Esbriet 1 GSK 6 2014 Lucentis Diabetic Retinopathy 3 Novartis 5 Anti-PDL1 (bladder) 4 Merck 4 Alectinib 2013 5 JNJ 4 Gazyva

Source: FDA 10 2015 outlook

Group sales growth1 Low to mid-single digit

Core EPS growth1 Ahead of sales growth2

Dividend outlook Further increase dividend in Swiss francs

1 At constant exchange rates 11 2 Excluding sale of filgrastim rights in 2014 Pharmaceuticals Division Daniel O’Day COO Roche Pharmaceuticals

12 Q1 2015 sales

Innovation

Outlook

13 Q1 2015: Strong sales growth driven by US and International

2015 2014 Change in % CHFm CHFm CHF CER Pharmaceuticals Division 9,322 9,040 3 4 United States 4,392 3,873 13 6 Europe 2,178 2,425 -10 1 Japan 763 845 -10 -2 International 1,989 1,897 5 9

CER=Constant Exchange Rates 14 Q1 2015: Strong performance from oncology and immunology franchises; Esbriet off to a good start

Herceptin +12%

Perjeta +82%

Esbriet n.a.

MabThera/Rituxan +5%

Avastin +6%

Kadcyla +80%

Actemra/RoActemra +27%

Xolair +28%

Lucentis -9% US Valcyte/Cymevene -41% Europe Pegasys -39% Japan International Xeloda -53%

-200 -150 -100 -50 0 50 100 150 200 CHFm

Absolute amounts and growth rates at Constant Exchange Rates (CER) 15 Q1 2015: Oncology products with +6% growth

YoY CER growth

Perjeta • Strong uptake of Perjeta & Kadcyla HER2 Herceptin +23% +23% • Accelerated growth of Herceptin Kadcyla • US: Continued uptake in ovarian, cervical and lung Avastin +6%+6% • EU: Growth in ovarian and breast

MabThera/ Rituxan +4% • Increased usage across a variety of indications

Tarceva --3%3% • In-class competition

Xeloda --53%53% • Loss of exclusivity

• Competitive pressure in US & EU Zelboraf --25%25% • Approval of coBRIM expected in 2015

CHFbn 0 1 2

CER=Constant Exchange Rates; Q1 2015 Oncology sales: CHF 5.8bn 16

HER2 franchise: Growth of Perjeta also driving Herceptin sales

CHFm YoY CER growth 2'400 23% 23% 19% 23% 17% 20% 1'800 15% 7% 15%

1'200

600

0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 13 13 13 13 14 14 14 14 15 Kadcyla Perjeta Herceptin

CER=Constant Exchange Rates 17 Herceptin SC launched in 44 countries Conversion rate already exceeds 30%

Number of countries where SC share of Herceptin sales in Herceptin SC has been launched launched countries

50 35%

30% 40 25% 30 20%

20 15% 10% 10

Sales market (%) market Sales share 5% Total number of countries of countries number Total 0 0% Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 13 13 13 14 14 14 14 15 13 13 13 14 14 14 14 15

18 Avastin: Strong growth across various indications and in all regions

CHFm YoY CER growth 1'800 +9% +6% +11% Avastin Q1 2015 1'500 +1% • Main growth drivers are ovarian 1'200 (US; EU), lung (US) and cervical cancer (US) 900 • EU: Positive momentum in breast 600 cancer due to IMELDA • International (+11%) in all regions 300 Outlook 0 • EU launch in cervical cancer Q1 12 Q1 13 Q1 14 Q1 15 US Europe International Japan

CER=Constant Exchange Rates 19 Immunology franchise remains driven by Actemra, Xolair and MabThera/Rituxan

CHFm YoY CER growth 1'500 +20% • Actemra (+27%): SC launch and +11% +11% 1L monotherapy setting +5% 1'000 • Xolair (+28%): Allergic asthma and strong growth in Chronic Idiopathic Urticaria (CIU) post 500 FDA approval in Q1 ‘14

• MabThera/Rituxan (+11%): 0 Continues to grow in rheumatoid Q1 12 Q1 13 Q1 14 Q1 15 arthritis and vasculitis (GPA and Other (incl Esbriet) Pulmozyme MPA) CellCept Xolair Actemra SC Actemra IV MabThera/Rituxan

GPA=Granulomatosis with polyangiitis; MPA=Microscopic polyangiitis 20 CER=Constant Exchange Rates Ophthalmology franchise: Competitive pressure on Lucentis; Fast Track status for lampalizumab

USDm Lucentis sales Lucentis Q1 2015 500 • Continued competitive pressure in wAMD • First-in-class FDA approval to treat diabetic retinopathy (DR) in patients 400 with DME

AMD Less-frequent than Lucentis outlook monthly dosing • Ongoing competition in AMD & DME 300 Lucentis • First sales in DR DME Lampalizumab update • FDA granted Fast Track status for 200 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 geographic atrophy (GA) 12 12 12 12 13 13 13 13 14 14 14 14 15 • Ph3 global enrollment well on track

wAMD=wet age-related macular degeneration; DME=diabetic macular edema 21 Esbriet: Off to a strong start

Esbriet sales (CHFm)

88 US launch off to strong start

• Patients still in transition to full reimbursement post approval 44 • Establishing market leadership in IPF 36 32 27 European sales with continued growth • Label was strengthened by including ASCEND and pooled 1Y mortality data Q1 14 Q2 14 Q3 14 Q4 14 Q1 15

22 Q1 2015 sales

Innovation

Outlook

23 Gazyva: First positive readout in iNHL

CLL11: Ph III front-line chronic lymphocytic leukemia (CLL) Gazyva 1000mg IV + chlorambucil Front-line CLL MabThera/Rituxan + Primary end-point: PFS n=781 chlorambucil Approved in Q4 2013  chlorambucil

GADOLIN: Ph III MabThera/Rituxan refractory indolent non-Hodgkin`s lymphoma (iNHL) Induction Maintenance CR, PR, Gazyva SD Gazyva + bendamustine q2mo x 2 years MabThera-refractory iNHL x 6 cycles Primary end-point: PFS n=411 Data at ASCO 2015 bendamustine  x 6 cycles

GOYA: Ph III diffuse large B-cell lymphoma (DLBCL)

Gazyva x 8 cycles + Front-line DLBCL CHOP x 6 or 8 Primary end-point: PFS (aggressive NHL) n=1,418 MabThera x 8 cycles + CHOP x Trial to continue until 2016 6 or 8

GALLIUM: Ph III front-line indolent non-Hodgkin`s lymphoma (iNHL) Induction Maintenance Gazyva x 8 cycles + CHOP x 6 or Gazyva Gazyva x 8 cycles + CVP x 8 or q2mo x 2 years Front-line iNHL Gazyva x 6 cycles + benda. x 6 Primary end-point: PFS n=1,401 CR, PR Enrolment complete Q1 2014 MabThera x 8 cycles + CHOP x 6 or MabThera x 8 MabThera Data expected 2017 cycles + CVP x 8 or MabThera x 6 cycles + benda. x 6 q2mo x 2 years

In collaboration with Biogen Idec 24 CHOP=Cyclophosphamide, Doxorubicin, Vincristine and Prednisone; CVP=Cyclophosphamide, Vincristine and Prednisolone Roche cancer immunotherapy Extensive phase III program to start in 2015 Phase I Phase II Phase III PDL1+Tarceva OX40 PDL1 PDL1 NSCLC Solid tumors NSCLC (Dx+) 2/3L NSCLC PDL1+Zelboraf CEA CD3 PDL1 PDL1** Melanoma Solid tumors 2/3L NSCLC 2/3L Bladder PDL1 IDO PDL1+Avastin PDL1+Avastin+chemo** Solid tumors Solid tumors 1L Renal 1L non sq NSCLC PDL1+Avastin PDL1+OX40** PDL1 PDL1+chemo** Solid tumors Solid tumors 1/2L Bladder 1L non sq NSCLC PDL1+cobimetinib PDL1+CSF-1R** PDL1+chemo** Solid tumors Solid tumors 1L sq NSCLC PDL1+ PDL1+CEA IL2v** PDL1** Solid tumors Solid tumors 1L non sq NSCLC (Dx+) PDL1+IFN-alfa PDL1+Zelboraf+cobi** PDL1** Solid tumors Solid tumors 1L sq NSCLC (Dx+) PDL1+CD40 PDL1** PDL1+chemo** Solid tumors tba 1L TNBC PDL1+Avastin+FOLFOX PDL1** PDL1+Avastin** CRC tba 1L RCC PDL1 + Gazyva PDL1** PDL1** Blood cancer tba tba Anti-PDL1 trials PDL1 PDL1** TNBC NMEs monotherapy tba CSF-1R Immune doublets Solid tumors 2015 readout expected CEA IL2v Solid tumors ** Study start in 2015 Status as at April 22, 2015 25 Breakthrough Therapy Designation granted for anti-PDL1 in 2/3L NSCLC in Q1

FIR: Ph II Dx-selected advanced metastatic Non-Small Cell Lung Cancer (mNSCLC)

PDL1-selected NSCLC anti-PDL1 1200 mg IV Primary end-point: ORR n = 138 Q3 weeks Data at ASCO 

POPLAR: Ph II 2/3L mNSCLC docetaxel All comers 2/3L NSCLC 75 mg/m2 IV Q3 wk (stratified by PDL1 Primary end-point: OS expression) anti-PDL1 Interim data at ASCO  n = 287 1200 mg IV Q3 wk Final data in H2 2015

BIRCH: Ph II Dx-positive advanced mNSCLC

PDL1-selected NSCLC anti-PDL1 1200 mg IV Primary end-point: ORR n = 667 Q3 weeks Data in Q3 2015

OAK: Ph III 2/3L mNSCLC docetaxel All comers 2/3L NSCLC 75 mg/m2 IV Q3 wk Primary end-point: OS (stratified by PDL1 FPI Q1 2014 expression) anti-PDL1 Data expected 2016 n = 1100 1200 mg IV Q3 wk

Note: Anti-PDL1 is listed as MPDL3280A in clinicaltrials.gov 26 Five anti-PDL1 phase III studies started addressing the entire 1L metastatic lung cancer market

Primary Study Indication Patient population Treatment arms n completion*

Combination studies

All comers carbo /pac/anti-PDL1 1L Non-squamous GO29436 (PD-L1 subgroup carbo/pac/Avastin/anti-PDL1 1,200 2017 (PFS) NSCLC analysis) carbo/pac/Avastin All comers 1L Non-squamous carbo/nab-p/anti-PDL1 GO29537 (PD-L1 subgroup 550 2017 (PFS) NSCLC carbo/nab-p analyis) All comers carbo /pac/anti-PDL1 1L Squamous GO29437 (PD-L1 subgroup carbo/nab-p/anti-PDL1 1,200 2017 (PFS) NSCLC analysis) carbo/nab-p

Monotherapy studies

1L Non-squamous anti-PDL1 GO29431 PD-L1 selected 400 2017 (PFS) NSCLC cis or carbo/pem

1L Squamous anti-PDL1 GO29432 PD-L1 selected 400 2018 (PFS) NSCLC cis or carbo/gem

* Outcome studies are event driven, timelines may change, OS endpoint included for all studies

Carbo = Carboplatin; Pac = Paclitaxel; Nab-p = Nab-paclitaxel; Cis = Cisplatin; Pem = Pemetrexed; Gem = Gemcitabine 27 Note: Anti-PDL1 is listed as MPDL3280A in clinicaltrials.gov Anti-PDL1 phase III study announced in TNBC Updated phase I data presented at AACR TNBC a ORR, PD-L1+ ORR 24-Week PFS PD-L1 IC2/3 patientsa, nb Best vs PD- (95% CI) (95% CI) IHC (IC) Respons L1- ORR, e, b % b % 19% 27% 21 n (95% CI) (95% CI) (5-42) (7-47) 17% IHC 3 6 (1,60) 33% • Anti-PDL1 was generally well tolerated 67% (10,70) (n=54) IHC 2 3 (14,98) • Responses included IHC 1 - - - – 2 CRs (1 IC3 and 1 IC2) and 2 PRs (IC2) IHC 0 - - - – 3 of 4 responses ongoing • In addition, three patients recorded as PD appeared to experience pseudoprogression, with durable shrinkage of target and new lesions • Phase III study to start in H2 2015

a PD-L1 expression was centrally evaluated on tumor-infiltrating immune cells (ICs) based on an immunohistochemistry (IHC) assay; b IC0/1 patients not yet evaluable for efficacy Emens LA, et al. AACR 2015 28 Foundation Medicine (FMI) Molecular Information supporting drug development

Roche/FMI R&D Collaboration • Our phase III anti-PDL1 program is a 1. Comprehensive tumor analysis in primary focus of the collaboration Roche` Clinical Trials • We will use FMI's FoundationOne next generation DNA sequencing to look DNA & RNA at a spectrum of DNA mutations sequencing 2. We will innovate together • We will also be working with Foundation Medicine to develop RNA signatures that may be predictive of patient benefit Immunotherapy Blood based Panel continuous monitoring

Transaction closed in April 2015

29 Alzheimer’s disease: Renewed confidence in Aß hypothesis

Amyloid pathway and targets

Amyloid Precursor Protein (APP) oligomeric Aβ • Aducanumab (BIIB): Similar to fibrillar Aβ gantenerumab by measure of soluble Aβ target engagement

• Gantenerumab and crenezumab: Assessment on- going to inform next steps Cell membrane

gantenerumab crenezumab solanezumab aducanumab bapineuzumab BAN2401

Aß mAb's

30 Q1 2015 sales

Innovation

Outlook

31 ASCO 2015: Highlights in various cancer types

Skin Bladder • cobimetinib + Zelboraf: Ph III (coBRIM) in 1L • anti-PDL1: Ph I update in bladder

BRAF+ mM; PFS & biomarker update Breast • cobimetinib + Zelboraf: Ph Ib (BRIM7) in • Kadcyla + Perjeta: Ph III (MARIANNE) in 1L BRAF+ mM; OS update HER2+ mBC; primary data

Lung • Avastin + Letrozole: Ph III (CALGB40503) in 1L HR+ mBC • alectinib: Two Ph II in 2L ALK+ NSCLC • Herceptin + Perjeta: Ph II (NEOPSPHERE) in • anti-PDL1: Ph II interim (POPLAR) in 2/3L neoadjuvant HER2+ BC NSCLC Hematology • anti-PDL1: Ph II (FIR) in PDL1-selected advanced NSCLC • Gazyva: Ph III (GADOLIN) in R/R iNHL • Polatuzumab vedotin: Ph II (ROMULUS) • anti-PDL1: Ph I update in NSCLC interim data in R/R iNHL • anti-PDL1: Ph I data from chemo combinations in NSCLC • anti-PDL1: Biomarker analysis in NSCLC

Zelboraf in collaboration with Plexxikon; Cobimetinib in collaboration with Exelixis; Alectinib in collaboration with Chugai, Gazyva in 32 collaboration with Biogen Idec; Kadcyla in collaboration with ImmunoGen 2015: Key late-stage news flow

Compound H1/H2 Compound Indication Milestone Avastin Positive opinion Feb 27 Avastin Cervical cancer EU approval  Lucentis Approved Feb 9 Lucentis Diabetic retinopathy US approval  Regulatory Regulatory alectinib Q3 alectinib 2L ALK+ NSCLC US filing Cobimetinib + PDUFA date: August 11, 2015 Zelboraf cobimetinib + Zelboraf 1L Melanoma US, EU approval Gazyva Gazyva MabThera/Rituxan-refractory iNHL Ph III GADOLIN  Gazyva to be communicated in H1 Gazyva Front-line aNHL Ph III GOYA (interim) 2016  ocrelizumab Q2 ocrelizumab Relapsing MS (RMS) Ph III OPERA I/II Phase III Phase III readouts*  readouts* ocrelizumab Q3 ocrelizumab Primary progressive MS (PPMS) Ph III ORATORIO

Perjeta 2H at SABCS 2015 (planed) Perjeta 2L HER2+ mBC Ph III PHEREXA Kadcyla 2H Kadcyla HER2+ gastric cancer Ph II/III GATSBY Anti-PDL1 1H anti-PDL1 ** 2/3L Bladder Ph III  Anti-PDL1 1H (RCC) anti-PDL1 ** 1L TNBC Ph III Anti-PDL1 1H (TNBC) anti-PDL1 ** 1L RCC Ph III Phase III Anti-PDL1 2H (MIBC) Phase III starts anti-PDL1 ** Tumor type 1 Ph III starts Etrolizumab 1H etrolizumab Crohn`s disease Ph III  ACE910 2H ACE910 Hemophilia A Ph III taselisib (PI3K 1H taselisib (PI3K inhib) HR+/PI3Kmut BC Ph III SANDPIPER inhib)  Anti-PDL1 1H (ASCO: FIR/POPLAR); 2H BIRCH anti-PDL1 2/3L NSCLC Ph II FIR, POPLAR, BIRCH Phase II Anti-PDL1 2H ESMO Phase II readouts* anti-PDL1 Bladder Ph II readouts* ipatasertib ipatasertib (AKT inhib) Gastric/prostate cancers Ph II A.MARTIN, JAGUAR ? (AKT inhib) * Outcome studies are event driven, timelines may change; ** For anti-PDL1 only P3 trials in new indications are listed (1L NSCLC 33 starts not shown) Diagnostics Division Roland Diggelmann COO Roche Diagnostics Picture

34 Q1 2015: Diagnostics Division sales Good growth in all units

2015 2014 Change in % CHFm CHFm CHF CER Diagnostics Division 2,511 2,456 2 6 Professional Diagnostics 1,425 1,392 2 6 Diabetes Care 507 538 -6 1 Molecular Diagnostics 401 370 8 10 Tissue Diagnostics 178 156 14 14

Underlying growth of Molecular Diagnostics excluding Sequencing Solutions: +8% 35 CER=Constant Exchange Rates Q1 2015: Diagnostics regional sales Strong performance in APAC

Japan North America -10% +5% EMEA1 4% of divisional sales 27% of divisional sales +4% 44% of divisional sales

Asia Pacific Latin America +16% +11% 19% of divisional sales 6% of divisional sales

16% growth in E7 countries2

1Europe, Middle East and Africa; 2Brazil, China, India, Mexico, Russia, South Korea, Turkey 36 All growth rates at Constant Exchange Rates Q1 2015: Diagnostics Growth driven by Professional Diagnostics

YoY CER growth

Professional +6% • Growth driven by immunodiagnostics (+11%) and Dia coagulation self testing (+14%)

Diabetes • Accu-Chek Aviva/Performa (+2%) and insulin +1% Care delivering systems (+10%)

Molecular • Virology (+10%) incl. HPV (+39%) +10% Dia 1 • Ariosa: Entry into NIPT

Tissue Dia +14% EMEA • Advanced staining portfolio (+13%) North America RoW Sales 0 0.5 1 1.5 CHFbn

1 Underlying growth of Molecular Diagnostics excluding Sequencing Solutions: +8% 37 CER=Constant Exchange Rates; EMEA=Europe, Middle East and Africa; NIPT=Non-invasive prenatal testing Professional Diagnostics: Global launch of cobas 8100 version 2

• Bidirectional sample flow between pre-analytical, analytical and post-analytical steps optimizes laboratory workflow • Automated sample check reduces work load and enhances patient safety

Integrated cobas 8100 lab solutions Elecsys assay menu

Post-analytics

Integrated Modular analyzers Pre-analytics

38 Immunoassays: 26% of Diagnostic sales growing double digit (+11%)

12% YoY CER growth

Sales 6% 10% 7%

14%

23%

30% 4%

9%

Cardiac Thyroid Tumor Women's Infectious Other Critical Care Anemia Hormones marker Health Diseases

39 CER=Constant Exchange Rates; “Other” include Needed Common Products, Allergy, Rheumatoid Arthritis, Immunosuppressants Molecular Diagnostics: Launch of HBV Test for cobas® 6800/8800 systems

Complements the viral load monitoring portfolio of cobas 6800/8800 • Lower sample requirement, higher sensitivity and faster test results across all genotypes • Strengthens market lead in viral load testing and helps optimize therapy for patients

Integrated cobas® 8800

Modular analyzers

Pre-analytics cobas® 8800

40 Roche sequencing: Delivering on acquisitions NEXT* study results demonstrate superiority of Harmony test vs conventional testing

Study results • Significant superiority of the HarmonyTM Prenatal Test over first trimester combined screening for assessing risk of Trisomy 21 • Lowers number of false positives which may reduce the need for invasive testing • Single largest trial > than 18,500 pregnant women • Supports the use of NIPT as a first line screening option

* NEXT: Non-invasive examination of trisomy; NIPT=Non-invasive prenatal testing 41 Key launches 2015

Area Product Market BA1 cobas c 513 – dedicated HbA1C analyzer EU RPD cobas t 411– core lab coagulation analyzer EU RPD Laboratory cobas 8100 V2 – Integrated pre- and post-analytical solution WW  RPD ® Instruments cobas 6800/8800 – Medium to High volume automated real-time PCR US RMD / VENTANA HE 600 – automated H&E staining platform WW RTD Devices Accu-Chek Active no-code– next-gen. bG meter, no coding of test strips Diabetes WW RDC – bG meter with connectivity to smartphones, mobile Care Accu-Chek Connect US RDC applications and cloud Point of Care CoaguChek® Pro II - professional system for PT and aPTT testing EU RPD Blood cobas® 6800/8800 MPX – Multiplex Bloodscreening test US RMD Screening Infectious cobas® Liat A/B + RSV – POC detection US RMD Diseases HTLV– human T-lymphotropic virus diagnostics test EU RPD ® Tests cobas 6800/8800 HBV – Quantitative HBV viral load test EU  RMD / cobas® 4800 HIV-1 - Quantitative HIV viral load test EU RMD Virology Assays cobas® 4800 HCV – Quantitative HCV viral load test EU RMD cobas® 4800 HBV – Quantitative HBV viral load test EU RMD Genomics & cobas® EGFR Test v2 - detection of EGFR in plasma EU RMD Oncology Cardiac Cobas h 232 Troponin T – Point of Care test version of Elecsys cTNT-hs EU RPD

1 Business Areas. RPD: Roche Professional Diagnostics; RDC: Roche Diabetes Care; RMD: Roche Molecular Diagnostics; 42 RTD: Roche Tissue Diagnostics; Finance Alan Hippe Chief Financial Officer

43 Q1 2015: Highlights

Currency impact • EUR and JPY currencies major negative contributors • Negative 2%p impact on Q1 2015 sales growth

Q1 debt refinancing and major cash outflows • Two bond redemptions – USD: 0.6 bn maturity in 2019 - coupon 6.00% s.a. – GBP: 0.5 bn maturity in 2015 - coupon 5.50% • Two bond issuances – USD: 0.6 bn maturity in 2020 - coupon 2.00% – EUR: 1.0 bn maturity in 2025 - coupon 0.875%

FMI transaction • Tender offer completed • Roche owns ~57% of the outstanding shares of FMI’s common stock on a fully diluted basis

s.a. = Semi-annual coupon 44 Q1 2015: Strong sales across the board

+6% +1% +9% -2%* +7% +1% +5% +3%

Pharma Division +4% +6 +140 -17 -221

+165 +18 +558 Dia Division +6% +337 +246

United Europe Intl. Chugai Dia Diabetes Group Fx1 Group States (Japan) Care CHF

Absolute values in CHFm at CER = Constant Exchange Rates (avg full year 2014) 1 avg December 2014 to avg March 2015 fx 45 * Japanese sales impacted by consumption tax base effect Exchange rate impact on sales growth USD and EUR impacts balance out

+0.2%p -0.1%p +2.8%p -0.6%p -0.6%p -0.9%p

-2.7%p

CER sales growth CHF Q1 2015 sales vs. +4.8% growth Q1 2014 Q1 2015 +2.9% vs. Q1 2014

CER USD Asia- Other Lat-Am JPY Other EUR CHF Pac Europe

CER=Constant Exchange Rates 46 Negative currency impact in 2015 expected

CHF / USD Assumed average YTD 2015

0.95 0.96 0.96 0.96 5% Average 7% 7% 8% 0.91 YTD +1% Assuming the 31 Mar 2015 exchange 2014 +1% 0.90 0.89 0.89 rates remain stable until end of 2015, 0.95 0.93 0.98 0.97 0.97 0.97 0.97 0.97 0.97 0.97 0.97 0.97 2015 impact is expected to be (%p): Monthly avg fx rates 2015 Fx rates at 31 March 2015 J F M A M J J A S O N D Q1 HY Sep FY YTD

CHF / EUR Sales -2 -2 -3 -3 1.22 1.22 1.22 1.21 Core operating -3 -4 profit -12% -13% -13% -13% +2%1.08 +2% Core EPS -7 -8 1.06 1.06 1.05

1.10 1.06 1.06 1.05 1.05 1.05 1.05 1.05 1.05 1.05 1.05 1.05

J F M A M J J A S O N D

47 Roche: Net trade working capital Continuous improvements over the years

Group NTWC / sales Accounts payable • Renegotiated existing supply payment terms 31.6% 31.1% • Simplified downstream processes • Established standard payment terms 29.7%

Accounts receivable • Southern Europe: Reduced accounts receivables • Eastern Europe: Adopted EU payment terms • Pro-active collection strategy

Dec-2012 Dec-2013 Dec-2014

Note: NTWC calculated as Q4 average for all years; NTWC 2014 excl. Esbriet inventory step-up

48 2015 outlook

Group sales growth1 Low to mid-single digit

Core EPS growth1 Ahead of sales growth2

Dividend outlook Further increase dividend in Swiss francs

1 At constant exchange rates 49 2 Excluding sale of filgrastim rights in 2014 Pipeline summary

Marketed products additional indications

Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED ( Research & Early Development)

Roche Group Q1 2015 results

Diagnostics

Foreign exchange rate information 50 Changes to the development pipeline Q1 2015 update New to Phase I New to Phase II New to Phase III New to Registration 1AI 1 NME (Trophos acquisition) 1 NME RG7813 CEA IL2v + PD-L1MAb - solid RG6083 olesoxime - SMA RG7604 taselisib - ER+/HER2- tumors 1 NME (shown to reflect upcoming neg mBC submission) 7 AIs RG7853 alectinib - ALK-mut. pos. RG7413 etrolizumab - Crohn’s NSCLC 2L disease 1 AI (previous P2 in solid tumors RG7446 PD-L1 MAb Dx-pos. split out) patients - NSCLC sq. 1L RG7604 taselisib - NSCLC sq. 2L RG7446 PD-L1 MAb Dx-pos. patients - NSCLC non-sq. 1L RG7446 PD-L1 MAb + chemo - NSCLC sq. 1L RG7446 PD-L1 MAb + chemo - NSCLC non sq. 1L RG7446 PD-L1 MAb + chemo +/- Avastin - NSCLC non sq. 1L RG7853 alectinib Alk-mut.pos. - NSCLC 1L Removed from Removed from Phase I Removed from Phase II Removed from Phase III Registration 2 NMEs 2 NMEs 1 AI 1 AI following US approval RG7410 TAAR1 ago - schizophrenia RG7790 setrobuvir – HCV RG435 Avastin - NSCLC adj. RG3645 Lucentis - diabetic RG7342 mGlu5 PAM - schizophrenia RG7321 pictilisib – solid tumors retinopathy 1 AI following EU approval RG435 Avastin – cervical cancer

Status as of April 22, 2015 51 Roche Group development pipeline

Phase I (31 NMEs + 12 AIs) Oncology Other disease areas

RG6016 LSD1 inh AML RG7625 - autoimmune diseases RG6047 SERD (2) ER+(HER2-neg) mBC RG7880 - inflammatory diseases RG6061 HIF1 alpha LNA solid tumors RG6080 DBO β-lactamase inh bact. RG6078 IDO inh solid tumors RG7689 - infectious diseases RG7116 lumretuzumab (HER3 MAb) solid tumors RG7795 TLR7 agonist HBV RG7155 (CSF-1R) + PDL1 s.tumors RG7641 aldosterone synth inh met. diseases RG7304 Raf & MEK dual inh solid tumors RG7203 PDE10A inh schizophrenia RG7388 idasanutlin (MDM2 ant) s. & hem tumors RG7345 TAU MAb Alzheimer’s RG7446 PD-L1 MAb solid tumors RG7893 Nav1.7 inh pain RG7446 PD-L1+Zelboraf+/-cobimetinib melanoma RG7800 SMN2 splicer spinal muscular atrophy RG7446 PD-L1+Avastin+chemo solid tumors RG7935 a-synuclein MAb Parkinson's Disease RG7446 PD-L1 MAb+cobimetinib solid tumors RG3645 Lucentis sust. deliv. AMD/RVO/DME RG7446 PD-L1 MAb+ipi/IFN solid tumors RG7716 VEGF-ANG2 MAb wAMD RG7446 PD-L1 MAb+Tarceva NSCLC EGFR+ New Molecular Entity (NME) RG7446 PD-L1 MAb+Gazyva lymphoma Additional Indication (AI) RG7450 Steap 1 ADC prostate ca. RG7597 (HER3/EGFR)+ cobi s. tum. Oncology Immunology RG7601 venetoclax heme indications Infectious Diseases RG7601 venetoclax+Gazyva CLL CLL CardioMetabolism RG7741 ChK1 inh solid tum & lymphoma Neuroscience Ophthalmology RG7775 MDM2 (4) IV prodrug AML Other RG7787 MSLN PE cFP solid tumors RG7802 CEA CD3 TCB solid tumors RG-No Roche Genentech managed CHU Chugai managed RG7813 CEA IL2v solid tumors

RG7813 CEA IL2v + PD-L1 MAb solid tumors RG7841 ADC solid tumors RG7842 ERK inh solid tumors RG7876 CD40 iMAb+PD-L1 MAb solid tumors RG7882 ADC ovarian ca RG7888 OX40 MAb solid tumors 52 Status as of April 22, 2015 Roche Group development pipeline Phase II (22 NMEs + 14 Als) Phase III (9 NMEs + 27 Als) Registration (1 NME + 2 Als) RG435 Avastin+Tarceva EGFR mut+ NSCLC RG435 Avastin glioblastoma 1L RG105 MabThera SC CLL RG3502 Kadcyla HER2+ NSCLC RG435 1 Avastin ovarian cancer 1L RG1273 2 Perjeta HER2+ BC neoadj RG6013 FIXa/FX bispecific MAb hemophilia A RG435 1 Avastin rel. ovarian ca. Pt-sensitive RG7421 cobimetinib + Zelboraf m. melanoma RG6046 SERD ER+(HER2-neg) mBC RG1273 Perjeta+Herceptin HER2+ mBC 2L RG7155 emactuzumab (CSF-1R) PVNS/s. tumors RG1273 Perjeta+Herceptin HER2+ BC adj RG7221 (Ang2-VEGF MAb) mCRC RG1273 Perjeta+Herceptin HER2+gastric ca 1L RG7421 cobimetinib+paclitaxel TNBC RG3502 Kadcyla HER2+ gastric cancer 2L 1 US only : FDA submission decision pending RG7440 ipatasertib solid tumors RG3502 Kadcyla +/- Perjeta HER2+ mBC 1L 2 Approved in US, submitted in EU RG7446 PD-L1 MAb NSCLC 2/3L RG3502 Kadcyla HER2+ BC adj * FPI imminent RG7446 PD-L1 MAb bladder cancer 1/2L RCC RG3502 Kadcyla + Perjeta HER2+ BC adj RG7446 PD-L1 MAb +Avastin RCC RG3502 Kadcyla + Perjeta HER2+ BC neoadj RG7596 polatuzumab vedotin hem tumors RG7159 Gazyva DLBCL1L ADCRG7599 lifastuzumab vedotin Pt-resist. OC RG7159 Gazyva iNHL -ref RG7601 venetoclax 17p del CLL rel/ref RG7159 Gazyva follicular lymphoma 1L RG7601 venetoclax DLBCL RG7204 Zelboraf melanoma adj RG7601 venetoclax+Rituxan FL rel/ref RG7446 PD-L1 MAb NSCLC 2L RG7604 taselisib NSCLC sq 2L RG7446 PD-L1+chemo NSCLC non-sq 1L

RG7604 taselisib ER+(HER2-neg) BC neoadj NSC RG7446 PD-L1+chemo+Avastin NSCLC non-sq 1L New Molecular Entity (NME) RG7686 glypican-3 MAb liver cancer RG7446* PD-L1+chemo NSCLC sq 1L Additional Indication (AI) RG7853 alectinib ALK+ NSCLC 2L RG7446* PD-L1 MAb Dx+ NSCLC sq 1L Oncology RG1569 Actemra systemic sclerosis RG7446* PD-L1 MAb Dx+ NSCLC non-sq 1L Immunology RG3637 lebrikizumab IPF RG7446 PD-L1 MAb bladder cancer 2L Infectious Diseases RG3637RG6062 lebrikizumabEsbriet SSc idiopathic–interstitial pulmonary lung disease fibrosis RG7601 venetoclax+Rituxan CLL rel/ref CardioMetabolism Neuroscience CHU IL-31R MAb atopic dermatitis RG7601 venetoclax+Gazyva CLL 1L Ophthalmology RG7227 danoprevir HCV RG7604 taselisib ER+(HER2-neg) mBC Other RG7745 Flu A MAb influenza RG7853 alectinib ALK+ NSCLC 1L RG-No Roche Genentech managed RG1569 Actemra giant cell arteritis RG7929 LptD antibiotic antibacterial CHU Chugai managed RG7697 GIP/GLP-1 dual ago type 2 diabetes RG3637 lebrikizumab severe asthma RG105 MabThera is branded as Rituxan CHU URAT 1 inh gout RG7413 etrolizumab ulcerative colitis in US and Japan RG1569 Actemra is branded as RoActemra RG7413 etrolizumab Crohn’s disease RG1577 sembragiline (MAO-B inh) Alzheimer’s in EU RG1662 GABRA5 NAM Down Syndrome CHU Actemra large-vessel vasculitis RG7159 Gazyva is branded as Gazyvaro in EU RG1678 bitopertin obsessive compulsive dis. CHU IL-6R MAb neuromyelitis optica RG7929RG6083 olesoxime spinal muscular atrophy RG1450 gantenerumab Alzheimer’s RG7090 basimglurant TRD RG1594 ocrelizumab RMS RG7314 V1 receptor antag autism RG1594 ocrelizumab PPMS 53 RG7412 crenezumab Alzheimer’s RG7417 lampalizumab geographic atrophy Status as of April 22, 2015 NME submissions and their additional indications

Projects currently in phase 2 and 3 GABRA5 NAM (RG1662) Down syndrome

bitopertin (RG1678) obsessive compulsive dis.

taselisib ( RG7604) basimglurant (RG7090) ER+(HER2-neg) BC neoadj depression

SERD (RG6046) taselisib ( RG7604) V1 receptor antag (RG7314) ER+(HER2-neg) mBC NSCLC sq 2L autism New Molecular Entity

Oncology FIXa/FX bispecific MAb PDL1 MAb (RG7446) crenezumab (RG7412) Immunology (RG6013) hemophilia A NSCLC sq 1L (Dx+) Alzheimer‘s Infectious Diseases CardioMetabolism emactuzumab (RG7155) PDL1 MAb (RG7446) sembragiline (RG1577) Neuroscience PVNS and solid tumors NSCLC non-sq 1L (Dx+) Alzheimer‘s Ophthalmology Other vanucizumab (RG7221) PDL1 MAb (RG7446)+ gantenerumab (RG1450) colorectal cancer chemo NSCLC sq 1L Alzheimer‘s

ipatasertib PDL1 MAb (RG7446)+ lebrikizumab (RG3637) (RG7440) solid tumors chemo NSCLC non-sq 1L idiopathic pulmonary fibrosis

ocrelizumab (RG1594) polatuzumab vedotin (RG7596) PDL1 MAb (RG7446)+chemo etrolizumab (RG7413) PPMS heme tumors + Avastin NSCLC non-sq 1L Crohn’s disease

lebrikizumab (RG3637) lifastuzumab (RG7599) cobimetinib+paclitaxel etrolizumab (RG7413) severe asthma Pt resistant OC TNBC ulcerative colitis

PDL-1 MAb (RG7446) olesoxime (RG6083) taselisib (RG7604) venetoclax (RG7601) danoprevir* (RG7227) bladder cancer SMA HER2 neg ER+ mBC + Rituxan FL rel/ref HCV

ocrelizumab (RG1594) PD-L1 MAb (RG7446) PDL-1 MAb (RG7446) glypican-3 MAb (RG7686) venetoclax (RG7601) Flu A MAb (RG7745) RMS NSCLC 2/3L combo Avastin RCC liver cancer + Gazyva CLL 1L influenza

alectinib (RG7853) venetoclax (RG7601) alectinib (RG7853) lampalizumab (RG7417) venetoclax (RG7601) LptD antibiotic (RG7929) Alk+ NSCLC 2L CLL rel/ref Alk+ NSCLC 1L geographic atrophy DLBCL antibacterial 2015 2016 2017 2018 and beyond

* lead market China Unless stated otherwise, submissions are planned to occur in US and EU 54 Status as of April 22, 2015 Submissions of additional indications for existing products Projects currently in phase 2 and 3

Gazyva iNHL rituximab refractory

*Avastin (US) ovarian cancer 1st L

*Avastin (US) Zelboraf Kadcyla rel. ovarian ca. Pt-sens melanoma adj. HER2+ NSCLC

Avastin +Tarceva(EU) Gazyva Kadcyla+Perjeta EGFR mut+ NSCLC DLBCL 1L HER2+ BC neoadj

Avastin (US) Perjeta + Herceptin Kadcyla+Perjeta GBM HER2+ mBC 2L HER2+ BC adj

Kadcyla +/- Perjeta Perjeta + Heceptin Gazyva Kadcyla HER2+ mBC 1L HER2+ BC adj follicular lymphoma 1L HER2+ BC adj

Kadcyla Actemra Perjeta+Herceptin Actemra HER2+ gastric cancer 2L giant cell arteritis HER2+ gastric cancer 1L systemic sclerosis 2015 2016 2017 2018 and beyond

Oncology Neuroscience Immunology Ophthalmology * approved in EU Infectious Diseases Other Unless stated otherwise, submissions are planned to occur in US and EU CardioMetabolism NME

Status as of April 22, 2015 55 Major granted and pending approvals 2015

Approved Pending approvals

Lucentis cobimetinib + Zelboraf US diabetic retinopathy m. melanoma February 2015 Filed December 2014

Avastin Perjeta cervical cancer HER2+ BC neoadj April 2015 Filed September 2014

cobimetinib + Zelboraf EU m. melanoma Filed September 2014

MabThera SC CLL Filed November 2014

Xeloda gastric cancer adj Filed December 2014 Japan-Chugai Bonviva osteoporosis (oral) Filed February 2015

Oncology Neuroscience Immunology Ophthalmology Infectious Diseases Other CardioMetabolism NME

Status as of April 22, 2015 56 Cancer immunotherapy pipeline overview

Phase I Phase II Phase III (7 NMEs + 9 AIs) (1NME + 3 Als) (1NME + 6AIs)

RG6078 IDO inh solid tumors RG7155 emactuzumab (CSF-1R) PVNS/s. tumors RG7446 PD-L1 MAb NSCLC 2L RG7155 emactuzumab (CSF-1R) + PDL1 s.tumors RG7446 PD-L1 MAb NSCLC 2/3L RG7446 PD-L1+chemo NSCLC non-sq 1L RG7446 PD-L1 MAb solid tumors RG7446 PD-L1 MAb bladder cancer 1/2L RCC NSC RG7446 PD-L1+chemo+Avastin NSCLC non-sq 1L RG7446 PD-L1+Zelboraf+/-cobimetinib melanoma RG7446 PD-L1 MAb +Avastin RCC RG7446 PD-L1+chemo NSCLC sq 1L RG7446 PD-L1+Avastin+chemo solid tumors RG7446 PD-L1 MAb Dx+ NSCLC sq 1L RG7446 PD-L1 MAb+cobimetinib solid tumors RG7446 PD-L1 MAb Dx+ NSCLC non-sq 1L RG7446 PD-L1 MAb+ipi/IFN solid tumors RG7446 PD-L1 MAb bladder cancer 2L RG7446 PD-L1 MAb+Tarceva NSCLC EGFR+ RG7446 PD-L1 MAb+Gazyva lymphoma RG7802 CEA CD3 TCB solid tumors RG7813 CEA IL2v solid tumors RG7813 CEA IL2v + PD-L1 MAb solid tumors RG7876 CD40 iMAb+PD-L1 MAb solid tumors RG7888 OX40 MAb solid tumors *INCB PD-L1 MAb + IDO inh solid tumors *CDX PD-L1 MAb + varlilumab solid tumors

*external collaborations: INCB- Incyte INCB024360; CDX-1127- Celldex CD27 MAb Status as of April 22, 2015 57 Pipeline summary

Marketed products additional indications

Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development)

Roche Group Q1 2015 results

Diagnostics

Foreign exchange rate information 58 Avastin Ovarian cancer clinical development programme

Front-line metastatic Indication ovarian cancer Phase III Phase III Phase/study GOG-0218 ICON7

# of patients N=1,873 N=1,528

Design . ARM A: Paclitaxel and carboplatin for 6 cycles plus 5 cycles . ARM A: Paclitaxel and carboplatin for 6 cycles of concurrent placebo followed by placebo alone for up to 22 . ARM B: Paclitaxel and carboplatin plus concurrent Avastin for cycles (15 months) 6 cycles followed by Avastin alone for up to 18 cycles (12 . ARM B: Paclitaxel and carboplatin for 6 cycles plus 5 cycles months) of concurrent Avastin followed by placebo alone for up to 22 cycles (15 months) . ARM C: Paclitaxel and carboplatin for 6 cycles plus 5 cycles of concurrent Avastin followed by Avastin alone for up to 22 cycles (15 months)

Avastin dose . 15 mg/kg q3 weeks . 7.5 mg/kg q3 weeks

Primary . Progression-free survival . Progression-free survival endpoint

Status . Study met its primary endpoint in Q1 2010 . Study met its primary endpoint Q3 2010 . Data presented at ASCO 2010 and 2011 . Data presented at ESMO 2010 and ASCO 2011 . Results: NEJM 2011 Dec 29;365(26):2484-96 . Results: NEJM 2011 Dec 29;365(26):2473-83 . OS data presented at ECC 2013

. EMA approval granted Q4 2011 . Re-evaluate FDA submission in 2015

ASCO=American Society of Clinical Oncology; ESMO=European Society for Medical Oncology 59 Avastin Cervical and brain cancer clinical development programmes

Indication Stage IVB, recurrent or persistent cervical cancer Newly diagnosed glioblastoma

Phase III Phase III Phase/study GOG-240 AVAglio # of patients N=452 N=920

Design . ARM A: Paclitaxel, cisplatin . ARM A: Concurrent radiation and temozolomide . ARM B: Paclitaxel, cisplatin plus Avastin plus placebo; followed by maintenance TMZ plus . ARM C: Paclitaxel, topotecan placebo for 6 cycles; then placebo until disease . ARM D: Paclitaxel, topotecan plus Avastin progression . ARM B: Concurrent radiation and TMZ plus Avastin; followed by maintenance TMZ plus Avastin for 6 cycles; then Avastin (15mg/kg q3 weeks) monotherapy until disease progression

Avastin . 15 mg/kg q3 weeks . 10 mg/kg q2 weeks or 15 mg/kg q3 weeks dose

Primary . Overall survival . Progression-free survival endpoint . Overall survival

Status . Study met its primary endpoint Q1 2013 . Co-primary endpoint of PFS met Q3 2012 . Results published in NEJM Feb. 2014; 370(8):734-43 . Overall survival data presented at ASCO 2013 . Filed globally Q2 2014 . Filed in EU Q1 2013 . FDA approval granted Q3 2014 . Negative CHMP opinion Q3 2014 . Approved in EU Q1 2015 . US filing pending

TMZ=temozolomide 60 ASCO=American Society of Clinical Oncology Avastin Lung, breast and ovarian cancer development programmes

Adjuvant First-line HER2-negative metastatic Relapsed platinum-sensitive Indication lung cancer breast cancer ovarian cancer Phase III Phase III Phase III Phase/study ECOG 1505 MERiDiAN OCEANS

# of patients N=1,500 N=480 N=484

Design . ARM A: Cisplatin plus vinorelbine, . ARM A: Paclitaxel + Avastin . ARM A: Carboplatin, gemcitabine, docetaxel, gemcitabine or pemetrexed . ARM B: Paclitaxel + Placebo and concurrent placebo for 6-10 . ARM B: Cisplatin plus vinorelbine, cycles, followed by placebo alone until docetaxel, gemcitabine or pemetrexed disease progression plus Avastin up to 12 months . ARM B: Carboplatin, gemcitabine, and concurrent Avastin for 6-10 cycles, followed by Avastin alone until disease progression.

Avastin . 15 mg/kg q3 weeks . 10 mg/kg q2 weeks . 15 mg/kg q3 weeks dose

Primary . Overall survival . PFS in ITT . Progression-free survival endpoint . PFS in patients with high plasma VEGF-A

Status . Recruitment completed Q4 2013 . Co-primary endpoints met Q1 2015 . Study met its primary endpoint Q1 . Trial stopped for futility Q1 2015 . Data to be presented in 2015 2011 . EMA approval granted Q4 2012 . Final data presented at SGO 2014 . Re-evaluate FDA submission in 2015

SGO=Society of Gynecologic Oncology 61 Erivedge A novel small molecule inhibitor of the hedgehog signaling pathway

Locally advanced or metastatic Indication Idiopathic pulmonary fibrosis basal cell carcinoma

Phase II Phase/study Phase II STEVIE # of patients N=1,200 N=129

Design . Single ARM: 150 mg Erivedge . ARM A: Erivedge 150mg daily orally once daily . ARM B: placebo

Primary . Safety: Incidence of adverse events . Change in forced vital capacity (FVC) endpoint

Status . FPI Q2 2011 . FPI pending in anticipation of trial design amendment to incorporate new standard of care Esbriet

In collaboration with Curis 62 Esbriet Small molecule with activity in fibrotic diseases

Indication Systemic sclerosis-related interstitial lung disease (SSc-ILD)

Phase II Phase/study LOTUSS # of patients N=63

Design . Open-label, randomized, parallel-group, safety and tolerability study 2 week vs. 4 week dose titration regimens

Primary . Safety endpoint

Status . LPI Q3 2014 . Data to be presented at ATS 2015

ATS=Annual Meeting of American Thoracic Society 63 Gazyva/Gazyvaro Type II, glycoengineered anti-CD20

Previously untreated or Indication relapsed/refractory chronic lymphocytic Diffuse large B-cell lymphoma (DLBCL) leukemia Phase III Phase III Phase/study GREEN GOYA # of patients N=800 N=1,418

Design . Single-arm cohort study: Gazyva alone or in . ARM A: Gazyva 1000mg IV plus CHOP combination with different chemotherapy . ARM B: MabThera/Rituxan plus CHOP regimens (FC, Bendamustin or Clb), investigation of different strategies to reduce IRRs

Primary . Safety in combination with different . Progression-free survival endpoint chemotherapy regimens

Status . FPI Q4 2013 . Recruitment completed Q2 2014 . Initial safety data presented at ASH 2014 . Trial continues after interim analysis in 2015 . Final data expected in 2016

In collaboration with Biogen Idec 64 ASH=American Society of Hematology Gazyva/Gazyvaro Type II, glycoengineered anti-CD20 monoclonal antibody

Indolent Front-line indolent Indication non-Hodgkin’s lymphoma non-Hodgkin’s lymphoma MabThera/Rituxan refractory Phase III Phase III Phase/study GADOLIN GALLIUM Induction and maintenance study Induction and maintenance study # of patients N=411 N=1,401

Design . ARM A: Gazyva 1000mg IV plus bendamustine . ARM A: Gazyva 1000mg IV plus chemotherapy followed by Gazyva mainteinance followed by Gazyva maintenance . ARM B: bendamustine . ARM B: MabThera/Rituxan plus chemotherapy followed by MabThera/Rituxan maintenance

. Chemotherapy: . For follicular lymphoma: CHOP, CVP or bendamustine . For non-follicular lymphoma: physician’s choice

Primary . Progression-free survival . Progression-free survival endpoint

Status . Trial stopped at interim for efficacy Q1 2015 . Recruitment completed . Data to be presented at ASCO 2015 . Expect data in 2017 . Expect global filing in 2015

In collaboration with Biogen Idec 65 CHOP=Cyclophosphamide, Doxorubicin, Vincristine and Prednisone; CVP=Cyclophosphamide, Vincristine and Prednisolone Kadcyla Evaluating new treatment options in HER2-positive early breast cancer

HER2-positive neoadjuvant HER2-positive early breast Operable HER2-positive early Indication breast cancer cancer high-risk patients breast cancer Phase III Phase III Phase III Phase/study KRISTINE KATHERINE KAITLIN # of patients N=432 N=1,484 N=2,500

Design Before surgery patients will . ARM A: Kadcyla 3.6mg/kg q3w . Following surgery and receive 6 cycles of: . ARM B: Herceptin antracycline-based therapy: . ARM A: Herceptin plus Perjeta . ARM A: Herceptin 6mg/kg q3w plus docetaxel plus carboplatin plus Perjeta 420 mg/kg q3w . ARM B: Kadcyla plus Perjeta plus chemo . ARM B: Kadcyla 3.6mg/kg q3w After surgery patients will plus Perjeta 420mg/kg q3w plus receive: chemo . ARM A: Herceptin plus Perjeta . ARM B: Kadcyla plus Perjeta

Primary . Pathologic Complete Response . Invasive disease-free survival . Invasive disease-free survival endpoint (pCR) (IDFS) (IDFS)

Status . FPI Q2 2014 . FPI Q1 2013 . FPI Q1 2014

In collaboration with ImmunoGen, Inc. 66 Kadcyla Evaluating new treatment options in HER2-positive breast and gastric cancer

Previously untreated Previously treated locally advanced HER2-positive advanced (2L+) Indication HER2 pos. metastatic breast or metastatic HER2-positive gastric NSCLC cancer cancer Phase III Phase II/III Phase/study Phase II MARIANNE GATSBY # of patients N=1,092 N=412 N=40

Design . ARM A: Herceptin plus taxane . ARM A: Kadcyla 3.6mg/kg q3w . Single-agent Kadcyla 3.6 mg/kg . ARM B: Kadcyla 3.6mg/kg q3w plus . ARM B: Kadcyla 2.4mg/kg weekly Perjeta . ARM C: docetaxel or paclitaxel . ARM C: Kadcyla 3.6 mg/kg q3w plus placebo

Primary . Progression-free survival assessed . Phase II: Dose-finding . Overall response rate and safety endpoint by IRF . Phase III: Overall survival

Status . Study met non-inferiority endpoint, . Recruitment completed Q1 2015 . FPI Q4 2014 showing similar progression-free . Data expected in 2015 survival (PFS) among the three arms Q4 2014 . Study did not meet PFS superiority endpoint for Kadcyla-containing regimens Q4 2014 . Data to be presented at ASCO 2015

In collaboration with ImmunoGen, Inc. 67 ASCO=American Society of Clinical Oncology

MabThera/Rituxan Oncology development programme

Indication Previously untreated chronic lymphocytic leukemia

Phase Ib SAWYER Phase/study Subcutaneous study Study being conducted ex-US # of patients N=225

Design . Two-stage design: - Stage 1 (dose-finding, N=55)

- Stage 2 (N=170): CLL dose confirmation: . ARM A: MabThera IV plus chemotherapy (fludarabine and cyclophosphamide) . ARM B: MabThera 1600mg SC plus chemotherapy (fludarabine and cyclophosphamide)

Primary . Part 1: PK (dose selection) endpoint . Part 2: PK of MabThera IV versus MabThera SC (arm A vs. arm B)

Status . Stage 2 data confirmed non-inferior PK and comparable safety/efficacy of MabThera 1600mg SC vs. MabThera IV . Presented at ASH 2014 . Filed in EU Q4 2014

Subcutaneous MabThera : applies Enhanze technology, partnered with Halozyme 68 ASH=American Society of Hematology Perjeta First in a new class of HER dimerization inhibitors

Adjuvant HER2-positive breast Indication Neoadjuvant HER2-positive breast cancer cancer Phase II Phase II Phase III Phase/ study NEOSPHERE TRYPHAENA APHINITY # of patients N=417 N=225 N=4,803

Design . ARM A: Herceptin plus docetaxel . ARM A: FEC followed by Taxane . ARM A: Perjeta (840mg loading, . ARM B: Perjeta (840mg loading, with Herceptin and 420 q3w) plus Herceptin for 52 420mg q3w) plus Herceptin and (H+P given concurrently) weeks plus chemotherapy (6-8 docetaxel . ARM B: FEC followed by Taxane cycles) . ARM C: Perjeta plus Herceptin with Herceptin + pertuzumab (H+P . ARM B: placebo plus Herceptin (52 . ARM D: Perjeta plus docetaxel given sequentially) weeks) plus chemotherapy (6-8 . ARM C: TCH + pertuzumab (H+P cycles) given concurrently)

Primary . Pathologic complete response . Safety . Invasive disease-free survival (IDFS) endpoint (pCR)

Status . Positive data presented at SABCS . Positive safety and efficacy data . Recruitment completed Q3 2013 2010 presented at SABCS 2011 . Expect data in 2016 . Biomarker data presented SABCS 2011 . Survival data to be presented at ASCO 2015

. FDA approval granted Q3 2013 . Filed in EU Q3 2014

FEC = Fluorouracil, Epirubicin, and Cyclophosphamide; TCH = Docetaxel, Carboplatin, Herceptin; 69 SABCS=San Antonio Breast Cancer Symposium; ASCO=American Society of Clinical Oncology Perjeta First in a new class of HER dimerization inhibitors

Second-line HER2- Advanced HER2-positive Neoadjuvant/adjuvant HER2-positive Indication positive metastatic gastric cancer breast cancer breast cancer Phase/ Phase III Phase III Phase II study PHEREXA JACOB BERENICE # of patients N=450 N=780 N=400

Design . ARM A: Herceptin plus . ARM A: Perjeta (840mg Neoadjuvant treatment: Xeloda loading, 420mg q3w) plus . ARM A: ddAC q2w x4 cycles followed by . ARM B: Perjeta plus Herceptin and weekly paclitaxel for 12 weeks, with P+H x4 Herceptin and Xeloda chemotherapy cycles . ARM B: placebo plus . ARM B: FEC+P+H x4 cycles followed by Herceptin and docetaxel+P+H x4 cycles chemotherapy Adjuvant treatment: . P+H q3w to complete 1 year of HER2 therapy . Hormonal and radiation therapy as indicated

Primary . Progression-free survival . Overall survival . Safety endpoint

Status . Recruitment completed Q3 . FPI Q2 2013 . FPI Q3 2014 2013 . Expect data in 2015

ddAC=dose-dense doxorubicin plus cyclophosphamide; FEC = Fluorouracil, Epirubicin, and Cyclophosphamide 70 Zelboraf A selective novel small molecule that inhibits mutant BRAF

Adjuvant therapy in patients with resected Indication cutaneous BRAF mutation positive melanoma

Phase III Phase/study BRIM8

# of patients N=725

Design . 52-week treatment . ARM A: Zelboraf 960mg bid . ARM B: Placebo

Primary . Disease-free survival endpoint

Status . FPI Q3 2012

In collaboration with Plexxikon, a member of Daiichi Sankyo Group See also combinations with: cobimetinib (RG7421) and anti-PDL1 (RG7446) 71 Actemra/RoActemra Interleukin 6 receptor inhibitor

Indication Systemic sclerosis Giant Cell Arteritis

Phase II Phase III Phase/study faSScinate GiACTA Proof-of-concept study # of patients N=86 N=250

Design . Blinded 48-week treatment with weekly dosing: . Part 1: 52-week blinded period . ARM A: Actemra SC 162mg . ARM A: Actemra SC 162mg qw + 26 weeks . ARM B: Placebo SC prednisone taper . ARM B: Actemra SC 162mg q2w + 26 weeks Open-label weekly dosing at weeks 49 to 96: prednisone taper . Actemra SC 162mg . ARM C: Placebo+ 26 weeks prednisone taper . ARM D: Placebo+ 52 weeks prednisone taper

. Part II: . 104-week open label extension – patients in remission followed off of the study drug; Patients with active disease receive open label Actemra SC 162mg qw

Primary . Change in modified Rodnan skin score (mRSS) at week . Proportion of patients in sustained remission at week 52 endpoint 24 . Safety

Status . 48 week data presented at ACR 2014 . FPI Q3 2013 . Primary and all key secondary endpoints showed trend for improved efficacy

In collaboration with Chugai 72 ACR=American College of Rheumatology Pipeline summary

Marketed products additional indications

Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development)

Roche Group Q1 2015 results

Diagnostics

Foreign exchange rate information 73 Alectinib (ALK inhibitor, RG7853, AF802) New CNS-active inhibitor of anaplastic lymphoma kinase

Treatment naïve ALK-positive ALK-positive crizotinib-naïve Indication advanced NSCLC advanced NSCLC Phase I/II Phase III Phase/study AF-001JP ALEX Japanese study # of patients N=286 N=70

Design . ARM A: alectinib 600mg BID . Part 1: Dose escalation monotherapy . ARM A: crizotinib 250mg BID . Part 2: Monotherapy, dose selected based on the results of Part 1

Primary . Progression-free survival . Phase I: Determination of endpoint recommended dose . Phase II: Safety and efficacy

Status . FPI Q3 2014 . Results published in Lancet Oncology 2013 Jun;14(7):590-8 . Approved in Japan with brand name ALECENSA July 2014

In collaboration with Chugai 74 Alectinib (ALK inhibitor, RG7853, AF802) New CNS-active inhibitor of anaplastic lymphoma kinase

ALK-positive advanced NSCLC after ALK-positive advanced NSCLC after Indication progression on crizotinib treatment progression on crizotinib treatment

Phase I/II Phase I/II Phase/study AF-002JG/NP28761 ACCALIA/NP28673 US study Phase I: N=36 # of patients N=130 Phase II: N=85

Design . Part 1: Dose escalation monotherapy . Part 1: Dose escalation monotherapy . Part 2: Monotherapy, dose selected based on the . Part 2: Monotherapy, dose selected based on the results of Part 1 results of Part 1

Primary . Phase I: Determination of recommended dose . Phase I: Determination of recommended dose endpoint . Phase II: Safety and efficacy . Phase II: Safety and efficacy

Status . Phase I data presented at ECC 2013 . Phase II FPI Q3 2013 . Phase I full cohort including CNS data published . Primary analysis positive Q4 2014 in Lancet Oncology 2014, Sept.15(10):1119-28 . Updated analysis in Q1 2015 . Phase II FPI Q3 2013 . Data to be presented at ASCO 2015 . Primary analysis positive Q1 2015 . Data to be presented at ASCO 2015

. Expect global filing in 2015

. Breakthrough therapy designation granted by the FDA June 2013

In collaboration with Chugai ECC=European Cancer Congress; ASCO=American Society of Clinical Oncology 75 Anti-PDL1 (MPDL3280A, RG7446) Novel approach in cancer immunotherapy

1L non-squamous NSCLC Indication 1L non-squamous NSCLC 1L non-squamous NSCLC PD-L1-selected patients

Phase/study Phase III Phase III Phase III

# of patients N=400 N=1200 N=550

Design . ARM A: RG7446 monotherapy . ARM A: RG7446 + Avastin + . ARM A: RG7446 + nab- . ARM B: carboplatin or paclitaxel + carboplatin paclitaxel + carboplatin cisplatin + pemetrexed . ARM B: RG7446 + paclitaxel . ARM B: nab-paclitaxel + + carboplatin carboplatin . ARM C: Avastin + paclitaxel + carboplatin

Primary . Progression-free survival . Progression-free survival . Progression-free survival endpoint

Status . Expect FPI Q2 2015 . FPI Q1 2015 . FPI Q1 2015

76 Anti-PDL1 (MPDL3280A, RG7446) Novel approach in cancer immunotherapy

1L squamous NSCLC Indication 1L squamous NSCLC PD-L1-selected patients

Phase/study Phase III Phase III

# of patients N=400 N=1200

Design . ARM A: RG7446 monotherapy . ARM A: RG7446 + nab- . ARM B: gemcitabine + paclitaxel + carboplatin cisplatin or carboplatin . ARM B: RG7446 + paclitaxel + carboplatin . ARM C: nab-paclitaxel + carboplatin

Primary . Progression-free survival . Progression-free survival endpoint

Status . Expect FPI Q2 2015 . Expect FPI Q2 2015

77 Anti-PDL1 (MPDL3280A, RG7446) Novel approach in cancer immunotherapy

Locally advanced or Locally advanced or Locally advanced or Metastatic NSCLC Non-small cell lung Indication metastatic NSCLC metastatic NSCLC metastatic NSCLC 2nd line cancer PD-L1 positive PD-L1 positive (2nd/3rd line)

Phase III Phase II Phase II Phase II Phase/study Phase I OAK FIR BIRCH POPLAR

# of patients N=1100 N=130 N=635 N=287 N=32

Design . ARM A: RG7446 . Single arm study . Single arm study . ARM A: RG7446 . RG7446 plus 1200mg q3w . RG7446 1200mg q3w . RG7446 1200mg q3w 1200mg q3w Tarceva1 . ARM B: docetaxel . ARM B: docetaxel

Primary . Overall survival . Overall response rate . Objective response . Overall survival . Safety endpoint rate

Status . FPI Q1 2014 . Recruitment . Recruitment . Recruitment . FPI Q1 2014 completed Q2 2014 completed Q4 2014 completed Q2 2014 . Data to be presented . Readout in 2015 . Data to be presented at ASCO 2015 at ASCO 2015

1Tarceva is a registered trademark of OSI Pharmaceuticals, LLC, a subsidiary of Astellas US, LLC ASCO=American Society of Clinical Oncology 78 Anti-PDL1 (MPDL3280A, RG7446) Novel approach in cancer immunotherapy

Previously Untreated Locally advanced or Locally advanced or Indication Metastatic Triple Negative metastatic urothelial metastatic urothelial Breast Cancer bladder cancer bladder cancer

Phase/study Phase III Phase III Phase II

# of N=350 N=767 N=400 patients

Design . ARM A: RG7446 + nab- Patients who progressed on RG7446 1200mg q3w paclitaxel at least one platinum- . Cohort 1: Treatment-naive . ARM B: placebo + nab- containing regimen will and cisplatin-ineligible paclitaxel receive: patients . ARM A: RG7446 1200mg . Cohort 2: Patients with q3w disease progression . ARM B: chemotherapy following or during (vinflunine, paclitaxel or platinum-containing docetaxel) treatment

Primary . Progression-free survival . Overall survival . Objective response rate endpoint

Status . Expect FPI H2 2015 . FPI Q1 2015 . Recruitment completed Q1 2015 . Readout in 2015

79 Anti-PDL1 (MPDL3280A, RG7446) Novel approach in cancer immunotherapy

Indication Untreated advanced renal cell carcinoma

Phase/study Phase III Phase II

# of patients N=550 N=300

Design . ARM A: RG7446 plus Avastin . ARM A: RG7446 plus Avastin . ARM B: sunitinib . ARM B: RG7446; following PD: RG7446 plus Avastin . ARM C: sunitinib; following PD: RG7446 plus Avastin

Primary . Progression free survival . Progression free survival endpoint

Status . Expect FPI Q2 2015 . Recruitment completed Q1 2015 . Readout in 2015

80 Anti-PDL1 (MPDL3280A, RG7446) Novel approach in cancer immunotherapy

Locally advanced or Indication Solid tumors Solid tumors Solid tumors metastatic solid tumors

Phase/study Phase I Phase I Phase I Phase I # of patients N=160 N=110 N=360 N=200

Design . Part 1: sequential RG7446 in combination with . Stage 1: Dose escalation . ARM A: RG7446 plus administration of RG7446 RG7155 (anti-CSF1R) of RG7446 plus RG7888 ipilimumab and RG7876 (CD40 iMAb) . Part 1: dose escalation (anti-OX40) . ARM B: RG7446 plus . Part 2: concomitant . Part 2: expansion . Stage 2: Expansion alpha-2b administration of RG7446 RG7446 plus RG7888 (anti- and RG7876 OX40) . Part 3: study drugs schedule in specific indication per Part 2

Primary . Safety . Safety . Safety . Safety endpoint

Status . FPI Q4 2014 . FPI Q1 2015 . Expect FPI Q2 2015 . FPI Q3 2014

81 Anti-PDL1 (MPDL3280A, RG7446) Novel approach in cancer immunotherapy

Relapsed/Refractory follicular Indication Solid tumors lymphoma and DLBCL

Phase/study Phase I Phase I # of patients N=180 N=52

Design . ARM A: RG7446 + Avastin Stage 1: safety evaluation . ARM B: RG7446 + Avastin + . RG7446 plus Gazyva FOLFOX . ARM C: RG7446 + carboplatin + Stage 2: expansion paclitaxel . RG7446 plus Gazyva . ARM D: RG7446 + carboplatin+ pemetrexed . ARM E: RG7446 + carboplatin+ nab-paclitaxel . ARM F: RG7446 + nab-paclitaxel

Primary . Safety/PK . Safety endpoint

Status . FPI Q2 2012 . FPI Q4 2014 . Chemo combination data in NSCLC to be presented at ASCO 2015

82 Anti-PDL1 (MPDL3280A, RG7446) Novel approach in cancer immunotherapy

Previously untreated metastatic Indication Solid tumors melanoma BRAF mutation positive

Phase/study Phase I Phase I

# of patients N=180 N=44

Design . ARM A: RG7446 + Avastin . Dose-finding study of RG7446 + Zelboraf1 . ARM B: RG7446 + Avastin + FOLFOX and RG7446 + Zelboraf1 + cobimetinib2 . ARM C: RG7446 + carboplatin + paclitaxel combinations . ARM D: RG7446 + carboplatin+ pemetrexed . ARM E: RG7446 + carboplatin+ nab- paclitaxel . ARM F: RG7446 + nab-paclitaxel

Primary . Safety/PK . Safety/PK endpoint

Status . FPI Q2 2012 . FPI Q4 2012 . Chemo combination data in NSCLC to be presented at ASCO 2015

1Zelboraf in collaboration with Plexxikon, a member of Daiichi Sankyo Group; 2Cobimetinib in collaboration with Exelixis 83 Anti-PDL1 (MPDL3280A, RG7446) Novel approach in cancer immunotherapy

Previously untreated Previously untreated metastatic Indication metastatic melanoma BRAF Solid tumors melanoma BRAF mutation positive mutation positive

Phase/study Phase I Phase I Phase I

# of patients N=44 N=90 N=344

Design . Dose-finding study of RG7446 + . ARM A: Dose-finding – RG7446 . Dose escalation study Zelboraf1 and RG7446 + plus cobimetinib Zelboraf1 + cobimetinib2 . ARM B: Dose-expansion - RG7446 combinations plus cobimetinib

Primary . Safety/PK . Safety . Safety/PK endpoint

Status . FPI Q4 2012 . FPI Q4 2013 . FPI Q2 2011 . Initial efficacy data presented at ASCO 2013 . Updated data presented at ECC 2013 . Data from bladder cohort presented at ASCO and ESMO 2014 . Data from TNBC cohort presented at AACR 2015 . Updated lung and bladder data to be presented at ASCO 2015

1Zelboraf in collaboration with Plexxikon, a member of Daiichi Sankyo Group; 2Cobimetinib in collaboration with Exelixis ASCO=American Society of Clinical Oncology; ECC=European Cancer Congress; AACR=American Association for Cancer Research 84 ESMO=European Society for Medical Oncology Cobimetinib (RG7421, GDC-0973) Selective small molecule inhibitor of mitogen- activated protein kinase kinase

Previously untreated metastatic First-line metastatic triple negative Indication melanoma BRAF mutation positive breast cancer

Phase III Phase/study Phase II coBRIM

# of patients N=495 N=112

Design . ARM A: Zelboraf1 plus cobimetinib . ARM A: cobimetinib plus paclitaxel . ARM B: Zelboraf1 plus placebo . ARM B: placebo plus paclitaxel

Primary . Progression-free survival . Progression-free survival, safety endpoint

Status . Primary endpoint met Q3 2014 . FPI Q1 2015 . Data presented at ESMO and SMR 2014 . Results published NEJM 2014 Nov 13;371(20):1867-76 . Filed in EU Q3 2014 . Filed in US Q4 2014 . Priority review granted Q1 2015 . Updated data to be presented at ASCO 2015

In collaboration with Exelixis 1Zelboraf In collaboration with Plexxikon, a member of Daiichi Sankyo Group; ESMO=European Society for Medical Oncology; SMR=Society for Melanoma Research; NEJM=New England Journal of Medicine 85 Cobimetinib (RG7421, GDC-0973) Selective small molecule inhibitor of mitogen- activated protein kinase kinase

Previously untreated Locally advanced or Locally advanced or Indication metastatic melanoma BRAF metastatic tumors with metastatic tumors mutation positive mutant KRAS

Phase/study Phase I Phase I Phase I

# of patients N=90 N=44 N=50

Design . ARM A: Dose-finding - . Dose-finding study of . Dose finding of cobimetinib cobimetinib plus RG7446 (anti- RG7446+Zelboraf1 and plus RG7597 (anti-HER3/EGFR PDL1) RG7446+Zelboraf+ DAF) . ARM B: Dose-expansion - cobimetinib combinations cobimetinib plus RG7446 (anti- PDL1)

Primary . Safety . Safety/PK . Safety endpoint

Status . FPI Q4 2013 . FPI Q4 2012 . FPI Q4 2013

In collaboration with Exelixis 86 1Zelboraf In collaboration with Plexxikon, a member of Daiichi Sankyo Group Polatuzumab vedotin (RG7596) Antibody drug conjugate targeting CD79b for the treatment of B-cell malignancies

Relapsed or Refractory follicular Indication Non-Hodgkin's lymphoma Non-Hodgkin’s lymphoma lymphoma and DLBCL

Phase II Phase Phase Ib/II Phase Ib/II ROMULUS

# of patients N=228 N=90 N=224

Design . ARM A: plus . PhIb: dose escalation . PIb: dose escalation Rituxan . ARM B: polatuzumab vedotin plus . PhII: polatuzumab vedotin in . PhII: polatuzumab vedotin + BR vs. Rituxan combinaiton with Rituxan or Gazyva BR . ARM C: polatuzumab vedotin plus and CHP non-randomized . PhII expansion: polatuzumab vedotin Gazyva +Gazyva non-randomized

Primary . Safety and anti-tumor activity . Safety . Safety and response by PET/CT endpoint

Status . Recruitment in arms A&B completed . FPI Q4 2013 . FPI Q4 2014 Q1 2014 . Updated data presented at ASH 2014 . FPI in Gazyva arm C Q1 2015 . Updated data to be presented at ASCO 2015

In collaboration with Seattle Genetics ASH=American Society of Hematology; ASCO=American Society of Clinical Oncology 87 BR=bendamustine and Rituxan; CHP=Cyclophosphamide, Hydroxydoxorubicin, Prednisone Taselisib (RG7604, GDC-0032) Mutant-selective PI3 kinase inhibitor

HER2-negative ER-positive metastatic breast caner patients Neoadjuvant HER2-negative ER- Indication who progressed after aromatase positive breast cancer inhibitor therapy Phase III Phase II Phase SANDPIPER LORELEI

# of patients N=600 N=330

Design . ARM A: taselisib plus Fulvestrant . ARM A: taselisib plus letrozole . ARM B: placebo plus Fulvestrant . ARM B: placebo plus letozole

Primary . Progression-free survival . Response rate and pCR endpoint

Status . Expect FPI Q1 2015 . FPI Q4 2014

88 Taselisib (RG7604, GDC-0032) Beta isoform sparing PI3 kinase inhibitor targeting commonly mutated oncogene

HER2-negative HR-positive PI3KCAmut-pos. 2L squamous Solid tumors and HER2-negative Indicationx locally recurrent or metastatic NSCLC HR-positive breast cancer breast cancer Lung Master Protocol

Phase II Phase Phase I/II Phase I Lung-MAP

# of patients N=320 N=65 N=120

Design . Phase I . taselisib plus docetaxel . taselisib vs. chemo . taselisib . taselisib plus paclitaxel . taselisib plus letrozole or fulvestrant

. Phase II . taselisib (multiple doses) plus letrozole or fulvestrant

Primary . Safety/PK/efficacy . Safety . Progression-free survival endpoint

Status . Recruitment completed Q2 2014 . FPI Q2 2013 . FPI Q2 2014 . Updated data presented at SABCS 2014

SABCS=San Antonio Breast Cancer Symposium 89 Venetoclax (RG7601, ABT-199/GDC-0199) Novel small molecule Bcl-2 selective inhibitor

Untreated CLL patients with Relapsed or Refractory CLL Indication coexisting medical Relapsed or Refractory CLL with 17p deletion conditions Phase III Phase III Phase/study Phase II CLL14 MURANO

# of patients N=432 N=370 N=100

Design . ARM A: venetoclax plus . ARM A: venetoclax plus . Single-agent venetoclax Gazyva Rituxan . ARM B: chlorambucil plus . ARM B: Rituxan plus Gazyva bendamustine

Primary . Progression-free survival . Progression-free survival . Safety/MTD endpoint

Status . FPI Q4 2014 . FPI Q1 2014 . Recruitment completed Q2 2014 . Data expected in 2015

Joint project with AbbVie in collaboration with WEHI (The Walter and Eliza Hall Institute) CLL=Chronic Lymphocytic Leukemia; NHL=Non-Hodgkin's Lymphoma; SLL=Small Lymphocytic Lymphoma 90 ASCO=American Society of Clinical Oncology Venetoclax (RG7601, ABT-199/GDC-0199) Novel small molecule Bcl-2 selective inhibitor

Relapsed or Refractory Relapsed or Refractory Relapsed or Refractory Indication Relapsed CLL and SLL or previously untreated or previously untreated CLL CLL CLL Phase/stud Phase II Phase Ib Phase Ib Phase Ib y # of N=40 N=50 N=70 N=74 patients

Design . venetoclax after ibrutinib . Dose-escalation study in . venetoclax in combination . venetoclax in combination therapy combination with with MabThera/Rituxan with Gazyva . venetoclax after idelalisib MabThera/Rituxan and bendamustine therapy

Primary . Overall response rate . Safety/MTD . Safety/MTD . Safety/MTD endpoint

Status . FPI Q3 2014 . Recruitment completed . FPI Q2 2013 . FPI Q1 2014 Q1 2015 . Data presented at ASCO 2014

Joint project with AbbVie in collaboration with WEHI (The Walter and Eliza Hall Institute) CLL=Chronic Lymphocytic Leukemia; NHL=Non-Hodgkin's Lymphoma; SLL=Small Lymphocytic Lymphoma 91 ASCO=American Society of Clinical Oncology Venetoclax (RG7601, ABT-199/GDC-0199) Novel small molecule Bcl-2 selective inhibitor

Relapsed or Refractory Relapsed or Refractory Relapsed or Refractory Indication follicular non-Hodgkin’s Front-line DLBCL NHL CLL and NHL lymphoma

Phase II Phase I/II Phase/study Phase I Phase I CONTRALTO CAVALLI # of patients N=156 N=230 N=40 N=211

Design . ARM A: venetoclax plus Dose finding: . Dose escalation of . Dose-escalation study Rituxan . ARM A: venetoclax+R- venetoclax in combination . ARM B: venetoclax plus CHOP with Rituxan and Rituxan plus bendamustine . ARM B: venetoclax+G- bendamustine . ARM C: Rituxan plus CHOP bendamustine Expansion: . venetoclax+R/G-CHOP

Primary . Overall response rate . Safety and efficacy . Overall response rate . Safety/PK/Response rate endpoint

Status . FPI Q4 2014 . FPI Q2 2014 . FPI Q2 2012 . FPI Q2 2011 . Study resumed Q3 2013 . Updated CLL, SLL and NHL (DLBCL and FL) data presented at ASCO 2014

Joint project with AbbVie in collaboration with WEHI (The Walter and Eliza Hall Institute) 92 ASCO=American Society of Clinical Oncology Venetoclax (RG7601, ABT-199/GDC-0199) Novel small molecule Bcl-2 selective inhibitor

Indication Relapsed or refractory multiple myeloma Acute myelogenous leukemia (AML)

Phase/study Phase I Phase I Phase II Phase Ib

# of patients N=30 N=30 N=54 N=89

Design . Patients receiving . Dose escalation cohort . Dose escalation of . venetoclax (dose Bortezomib and . Safety expansion cohort venetoclax escalation) +decitabine Dexamethasone as . venetoclax (dose standard therapy: escalation) +azacitidine . Dose escalation cohort: venetoclax+bortezomib+de xamethasone . Safety expansion cohort: venetoclax+bortezomib+de xamethasone

Primary . Safety/MTD . Safety/MTD . Overall response rate . Safety endpoint

Status . FPI Q4 2012 . FPI Q4 2012 . FPI Q4 2013 . FPI Q4 2014 . Data presented at ASH 2014

Joint project with AbbVie in collaboration with WEHI (The Walter and Eliza Hall Institute) 93 Factor IXa/X bispecific (RG6013, ACE910) Factor VIII mimetic for treatment of hemophilia A

Indication Hemophilia A

Phase I Phase I/II Phase/study Study in Japan Study in Japan

# of patients N=82 N≈18

Design . Enrolled 64 HVs and 18 patients . Extension study in patients from phase 1

Primary . Exploratory efficacy and safety . Exploratory efficacy and safety endpoint

Status . Recruitment completed Q2 2014 . Recruitment completed Q4 2014 . Data presented at ASH 2014

In collaboration with Chugai 94 ASH=American Society of Hematology Bitopertin (GlyT-1, RG1678) A small molecule first-in-class glycin reuptake inhibitor (GRI)

Indication Obsessive-compulsive disorder

Phase II Phase/study SKYLYTE # of patients N=99

Design . 16-week treatment period . Background therapy of selective serotonin reuptake inhibitors (SSRI) •ARM A: bitopertin daily (30 mg) •ARM B: bitopertin daily (10 mg) •ARM C: placebo

Primary . Change in total score on Yale-Brown Obsessive Compulsive endpoint Scale

Status . Enrollment completed Q4 2014

95 Gantenerumab (RG1450) Fully human monoclonal antibody against amyloid-beta

Indication Prodromal Alzheimer’s Disease Mild Alzheimer’s Disease

Phase II/III Phase III Phase/study SCarlet RoAD Marguerite Road

# of patients N=799 N=1,000

Design . 104-week subcutaneous treatment period . 104-week subcutaneous treatment period . ARM A: gantenerumab (225 mg) . ARM A: gantenerumab . ARM B: gantenerumab (105 mg) . ARM B: placebo . ARM C: placebo

Primary . Change in CDR-SOB at 2 years . Change in ADAS-Cog and ADCS-ADL at 2 endpoint . Sub-study: change in brain amyloid by PET years (co-primary) at 2 years

Status . Phase I PET data: Archives of Neurology . FPI Q1 2014 2012 Feb;69(2):198-207 . Enrollment completed Q4 2013 . Dosing stopped due to futility Q4 2014

In collaboration with Morphosys CDR-SOB=Clinical Dementia Rating scale Sum of Boxes 96 Etrolizumab (RG7413) A humanized monoclonal antibody against beta 7 integrin

Indication Ulcerative colitis patients who are TNF naïve

Phase III Phase III Phase III Phase/study HIBISCUS I HIBISCUS II GARDENIA Induction study Induction study Sustained remission study

# of patients N=350 N=350 N=720

Design . ARM A: etrolizumab 105mg SC q4w . ARM A: etrolizumab 105mg SC q4w Time on treatment 54 weeks + adalimumab placebo + adalimumab placebo . ARM A: etrolizumab 105mg SC q4w . ARM B: etrolizumab placebo + . ARM B: etrolizumab placebo + + placebo IV adalimumab adalimumab . ARM B: placebo SC q4w + . ARM C: etrolizumab placebo + . ARM C: etrolizumab placebo + adalimumab SC adalimumab placebo adalimumab placebo

Primary . Induction of remission compared with . Induction of remission compared with . Proportion of patients in sustained endpoint placebo as determined by the Mayo placebo as determined by the Mayo clinical remission as determined by Clinic Score (MCS) at week 10 Clinic Score (MCS) at week 10 Mayo Clinic Score (MCS) at weeks 10, 30 and 54

Status . FPI Q4 2014 . FPI Q4 2014 . FPI Q4 2014

97 Etrolizumab (RG7413) A humanized monoclonal antibody against beta 7 integrin

UC patient who are TNF naïve and refractory or UC patient who are refractory or intolerant of TNF Indication intolerant to immunosuppressant and/or corticosteroid inhibitors treatment Phase III Phase III Phase/study LAUREL HICKORY Maintenance study Induction and maintenance study

# of patients N=350 N=800

Design Induction phase: Cohort 1 (open-label): . ARM A: open label etrolizumab 105mg SC q4w . ARM A: etrolizumab induction + placebo maintenance . ARM B: etrolizumab induction + maintenance Maintenance study: . ARM B: etrolizumab 105mg SC q4w Cohort 2 (blinded): . ARM C: placebo . ARM A: etrolizumab induction + maintenance . ARM B: placebo induction + maintenance

Primary . Maintenance of remission (at week 62) among randomized . Clinical Remission (Mayo Clinic Score, MCS) at Week 14 endpoint patients in remission at Week 10 as determined by the Mayo . Remission maintenance (by MCS, at Week 66) among Clinic Score (MCS) patients with remission at Week 14

Status . FPI Q3 2014 . FPI Q2 2014

UC=ulcerative colitis 98 Etrolizumab (RG7413) A humanized monoclonal antibody against beta 7 integrin

Indication Moderate to severe ulcerative colitis Moderate to severe ulcerative colitis

Phase II Phase III Phase/study SPRUCE COTTONWOOD Open label extension study Open label extension study

# of patients N=116 N=2,600

Design . Patients who were enrolled in EUCALYPTUS . Patients who were previously enrolled in study and meet enrollment criteria will receive etrolizumab phase III studies and meet etrolizumab 105 sc q4w enrollment criteria will receive etrolizumab 105 sc q4w

Primary . Safety . Long-term efficacy as determined by partial endpoint Mayo Clinic Score (pMCS) . Incidence of adverse events

Status . Recruitment completed . FPI Q3 2014

99 Etrolizumab (RG7413) A humanized monoclonal antibody against beta 7 integrin

Moderately to severely active Crohn's Moderately to severely active Crohn's Indication disease disease

Phase III Phase III Phase/study BERGAMOT JUNIPER

# of patients N=1,250 N=1,250

Design . ARM A: etrolizumab SC 210 mg (induction . Etrolizumab SC 105mg q4w only) . ARM B: etrolizumab SC 105 mg and maintainance . ARM C: placebo

Primary . Induction and maintenance of clinical . Safety endpoint remission

Status . FPI Q1 2015 . Expect FPI Q2 2015

100 HCV: Danoprevir (RG7227) IFN-based triple regimen for treatment-naïve patients of Asian origin conducted in China

Treatment-naïve patients of Asian origin with chronic Indication genotype 1 with or without cirrhosis Phase II Phase/study DAPSANG # of patients N=61

Design . Without cirrhosis: . ARM A: Danoprevir 125 mg bid + 100mg bid+ Pegasys + Copegus for 12 weeks

. With compensated cirrhosis: . ARM B: Danoprevir 125 mg bid + Ritonavir 100mg bid+ Pegasys + Copegus for 24 weeks

Primary . Safety endpoint

Status . Recruitment completed Q4 2013 . Results presented at APASL 2015

In collaboration with Ascletis 101 APASL=Asian Pacific Association for the Study of the Liver Lampalizumab (RG7417) Antibody fragment to selectively block activation of alternative complement pathway

Indication Geographic atrophy (GA) secondary to age-related macular degeneration

Phase III Phase III Phase/study Phase II CHROMA SPECTRI # of patients N=936 N=936 N=100

Design . ARM A: lampalizumab 10mg q4w . ARM A: lampalizumab 10mg q4w . ARM A: lampalizumab 10mg q2w . ARM B: lampalizumab 10mg q6w . ARM B: lampalizumab 10mg q6w . ARM B: lampalizumab 10mg q4w . ARM C: placebo . ARM C: placebo . ARM C: placebo

. Primary: change in GA area . Primary: change in GA area . Change in GA area Primary . Secondary: change in BCVA and in . Secondary: change in BCVA and in endpoint additional measures of visual additional measures of visual function function

Status . FPI Q3 2014 . FPI Q3 2014 . FPI Q4 2014 . Design presented at EURETINA . Design presented at EURETINA 2014 2014 . Fast track designation received Q4 . Fast track designation received Q4 2014 2014

EURETINA=European Society of Retina Specialists 102 Lebrikizumab (RG3637) A humanized monoclonal antibody designed to bind specifically to IL-13

Severe uncontrolled adult asthma Adult patients whose Indication asthma is uncontrolled with inhaled corticosteroids and a second controller medication Phase III Phase III Phase/study LAVOLTA I LAVOLTA II # of N=1,050 N=1,050 patients

Design . Subcutaneous lebrikizumab q4w on top of SOC for . Subcutaneous lebrikizumab q4w on top of SOC for 52 weeks safety follow-up 52 weeks safety follow-up . ARM A: lebrikizumab high dose . ARM A: lebrikizumab high dose . ARM B: lebrikizumab low dose . ARM B: lebrikizumab low dose . ARM C: placebo . ARM C: placebo . Patients will be tested for periostin level . Patients will be tested for periostin level

Primary . Rate of asthma exacerbations during the 52-week . Rate of asthma exacerbations during the 52-week endpoint placebo-controlled period placebo-controlled period

Status . Enrollment completed Q4 2014 . Enrollment completed Q4 2014 . Expect data in 2016 . Expect data in 2016

103 Lebrikizumab (RG3637) A humanized monoclonal antibody designed to bind specifically to IL-13

Adolescent patients whose asthma is uncontrolled with inhaled Indication Idiopathic pulmonary fibrosis corticosteroids and a second controller medication Phase III Phase II Phase/study ACOUSTICS RIFF

# of patients N=375 N=250

Design . Subcutaneous lebrikizumab q4w on top of SOC . ARM A: lebrikizumab SC q4w for 52 weeks with 52 week double-blind active . ARM B: placebo treatment extension . ARM C: lebrikizumab SC q4w + Esbriet . ARM A: lebrikizumab high dose, week 1-104 or . ARM D: Esbriet week 52-104 . ARM B: lebrikizumab low dose, week 1-104 or week 52-104 . ARM C: placebo, week 1-52

Primary . Rate of asthma exacerbations during the 52- . Progression-free survival endpoint week placebo-controlled period

Status . FPI Q3 2013 . FPI Q4 2013 (arms A&B) . Expect FPI Q2 2015 (arms C&D)

SOC=Standard of Care; OCS=Oral Corticosteroids 104 Lebrikizumab (RG3637) A humanized monoclonal antibody designed to bind specifically to IL-13

Adult asthma Indication Adult asthma mild-to-moderate patients Phase II Phase III Phase/study VOCALS STRETTO

# of patients N=225 N=300

Design . ARM A: lebrikizumab high dose SC . ARM A: lebrikizumab SC q4w q4w . ARM B: placebo . ARM B: lebrikizumab low dose SC q4w . ARM C: Montelukast . ARM C: placebo

. Relative change in OCS dose at week . Absolute change in FEV1 at week 12 Primary 44 endpoint

Status . FPI Q1 2014 . FPI Q2 2014

105 Lebrikizumab (RG3637) A humanized monoclonal antibody designed to bind specifically to IL-13

Moderate-to-severe atopic Indication Adult asthma dermatitis Phase II Phase/study CLAVIER Phase II Mechanistic biomarker study

# of patients N=120 N=200

Design . ARM A: lebrikizumab SC q4w Patients on topical corticosteroids . ARM B: placebo . ARM A: lebrikizumab dose 1 . ARM B: lebrikizumab dose 2 . ARM C: lebrikizumab dose 3 . ARM D: placebo

. Relative change in airway inflammation . Percentage of patients achieving a 50% Primary (eosinophils/mm2) at week 12 reduction in Eczema Area and Severity endpoint Index (EASI) score (EASI-50) from baseline to week 12

Status . FPI Q1 2014 . Expect FPI Q2 2015

106 Ocrelizumab (RG1594) 2nd generation anti-CD20 monoclonal antibody

Primary progressive Indication Relapsing multiple sclerosis (RMS) multiple sclerosis (PPMS)

Phase III Phase III Phase III Phase/study OPERA I OPERA II ORATORIO

# of patients N=800 N=800 N=630

Design . 96-week treatment period: . 96-week treatment period: . 120-week treatment period: . ARM A: Ocrelizumab 2x 300 mg . ARM A: Ocrelizumab 2x 300 mg . ARM A: Ocrelizumab 2x 300 mg iv followed by 600 mg iv every 24 iv followed by 600 mg iv every 24 iv every 24 weeks weeks weeks . ARM B: Placebo . ARM B: Interferon -1a . ARM B: Interferon -1a

Primary . Annualized relapse rate at 96 . Annualized relapse rate at 96 . Sustained disability progression endpoint weeks versus Rebif weeks versus Rebif versus placebo by Expanded Disability Status Scale (EDSS)

Status . Enrollment completed Q1 2013 . Enrollment completed Q1 2013 . Enrollment completed Q1 2013 . Expect data in H2 2015 . Expect data in H2 2015 . Expect data in H2 2015

107 Olesoxime (RG6083) Novel small molecule neuroprotectant that preserves mitochondrial function

Indication Spinal muscular atrophy

Phase II Phase/study Registrational study

# of patients N=165

Design . ARM A: olesoxime . ARM B: placebo

Primary . Motor function measure endpoint

Status . Study completed Q4 2013 . Presented at AAN 2014

Collaborator Trophos acquisition

108 Pipeline summary

Marketed products additional indications

Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development)

Roche Group Q1 2015 results

Diagnostics

Foreign exchange rate information 109 Oncology development programmes Small molecules

Idasanutlin MDM2 antagonist IV LSD1 inhibitor Raf/MEK inhibitor Molecule (MDM2 antagonist, prodrug (RG6016) (RG7304, CKI27) RG7388) (RG7775) Advanced cancers Indication Acute myeloid leukemia Acute Leukemia Solid tumors including AML Phase Phase I Phase I Phase I Phase I # of patients N=100 N=90 N=30 N=52

Design . Multiple ascending dose- Dose-escalation study . Multiple ascending . Dose-escalation to MTD escalation study . ARM A: patients with dose-escalation study advanced solid tumors . ARM B: patients with r/r AML

Primary . MTD . MTD . MTD . MTD and tumor endpoint assessment

Status . FPI Q1 2013 . FPI Q2 2014 . FPI Q1 2014 . Initiated Q4 2008 . Data presented at ASH . Enrollment stopped in 2014 Q4 2010 Collaborator Oryzon Genomics, S.A. Chugai

ASH=American Society of Hematology 110 Oncology development programmes Monoclonal antibodies

Anti-glypican-3 MAb Molecule (GC33, RG7686) Metastatic liver cancer 2L metastatic liver cancer Indication (hepatocellular carcinoma) (hepatocellular carcinoma) Phase Phase Ib Phase II

# of patients N= 40-50 N=185

Design . Study US monotherapy . Adaptive design study . Study Japan monotherapy Double blind randomized 2:1 RG7686: placebo . Dose escalation study in combo with SOC . Patients are stratified according to the level of GPC-3 expression in tumor

Primary . Safety and tolerability . Progression-free survival endpoint

Status . Recruitment completed Q4 2013 . Recruitment completed Q1 2013 . Data presented at ASCO 2014 . Data presented at ASCO 2014 . Further steps under evaluation . Further steps under evaluation

Collaborator Chugai

SOC=standard of care; ASCO=American Society of Clinical Oncology 111 Oncology development programmes Monoclonal antibodies (continued)

Lumretuzumab Vanucizumab Molecule (GE-huMAb HER3, RG7116) (Ang2-VEGF Mab, RG7221)

HER2-low and HER3- 1L mNSCLC of Metastatic colorectal Indication Solid tumors positive metastatic Solid tumors squamous histology cancer breast cancer

Phase II Phase Phase I Phase I Phase Ib/II Phase I McCAVE

# of patients N=105 N=40 N=53 N≈80 N=140

Design . Multiple ascending . Multiple ascending . RG7116 in combination . Multiple ascending . ARM A: Induction: dose study with dose of RG7116 in with carboplatin and dose study with Avastin+mFOLFOX-6; extension cohorts and combination with paclitaxel extension cohorts in followed by imaging sub-study Perjeta and paclitaxel solid tumors to assess maintenance: . Combination arms with the PD effects and Avastin+5-FU/LV HER1-targeted platinum-resistant . ARM B: Induction: therapies (erlotinib, ovarian cancer RG7221+mFOLFOX-6; ) followed by maintenance: RG7221+5-FU/LV

Primary . Safety, PK . Safety, PK . Safety, ORR . Safety, PK . PFS endpoint

Status . FPI Q4 2011 . FPI Q3 2013 . FPI Q4 2014 . FPI Q4 2012 . Recruitment completed . Initial data presented at . Dose escalation data Q2 2015 ASCO 2013 presented at ASCO 2014

ASCO=American Society of Clinical Oncology 112 Oncology development programmes Monoclonal antibodies (continued)

Emactuzumab CEA-IL2v Molecule (CSF-1R huMAb, RG7155) (RG7813)

Indication Solid tumors and PVNS Solid tumors Solid tumors Solid tumors

Phase Phase I/II Phase I Phase I Phase I

# of patients N≈140 N=110 N~110 N=75

Design . Multiple ascending dose RG7155 in combination with . Single and multiple dose . Part 1: dose escalation of study +/- paclitaxel with RG7446 (anti-PDL1) escalation study with RG7813 in combination wth extension cohorts . Part 1: dose escalation extension cohorts RG7446 (anti-PDLT) . Part 2: expansion . Part 2” dose expansion RG7813 in combination with RG7446 (anti-PDL1

Primary . Safety, PK, PD & . Safety . Safety, PK, PD . Safety, Efficacy, PK, PD endpoint preliminary clinical activity

Status . FPI Q4 2011 . FPI Q1 2015 . FPI Q4 2013 . Expect FPI in Q2 2015 . Biomarker data presented . Imaging data to be at AACR 2013 and AACR presented at ASCO 2015 2014 . Data presented at ASCO 2014 . Updated data to be presented at ASCO 2015

AACR=American Association for Cancer Research; ASCO=American Society of Clinical Oncology 113 Oncology development programmes Monoclonal antibodies (continued)

CD40 iMAb (RG7876) in MSLN PEcFP CEA CD3 T-cell bispecific (TCB) Molecule combination with anti-PDL1 (RG7787) (RG7802) (RG7446)

Indication MSLN-positive solid tumors CEA-positive solid tumors Solid tumors

Phase Phase I Phase Ia Phase I

# of patients N=133 N=90 N=160

Design . Part A: Single agent dose escalation . Multiple ascending dose study with . Part 1A: sequential administration of and extensions extension cohorts and imaging sub- RG7876 and RG7446 (anti-PDL1) . Part B: Combination of RG7787 and study . Part 1B: concomitant administration gemcitabine/nab-paclitaxel dose of RG7876 and RG7446 (anti-PDL1) escalation and extension . Part 2: multiple doses of concomitant RG7876 and RG7446 (anti-PDL1) . Part 3: study drugs schedule in specific indications per Part 2

Primary . Safety, PK, PD . Safety, PK, PD, imaging . Safety endpoint

Status . FPI Q4 2014 . FPI Q4 2014 . FPI Q4 2014

114 Neuroscience development programmes

PDE10A inhibitor GABRA5 NAM Molecule (RG7203) (RG1662)

Indication Schizophrenia Down Syndrome

Phase IIB Phase Phase I CLEMATIS

# of patients N=26 N=180

Design . Multiple dose, double-blind study in . For 26 weeks patients will receive: schizophrenia patients . ARM A: RG1662 120mg twice daily . ARM B: RG1662 120mg twice daily . ARM A: RG7203 plus risperidone . ARM C: Placebo . ARM B: placebo plus risperidone

Primary . Safety, tolerability, PK . Cognition and adaptive behavior endpoint

Status . Study completed Q1 2015 . FPI Q2 2014 . Results under internal review

NAM=Negative allosteric modulator; 115 Neuroscience development programmes

V1 receptor antagonist SMN2 splicing modifier Basimglurant Molecule (RG7314) (RG7800) (mGlu5 NAM, RG7090)

Adjunctive Treatment of Major Indication Autism Spinal muscular atrophy Depressive Disorder

Phase II Phase Ib Phase II Phase VANILLA MOONFISH Marigold

# of patients N=240 N=48 N=300

Design . Multi-center, randomized, . Randomized, double-blind, 12- . ARM A: basimglurant 0.5 mg double-blind, placebo-controlled week, placebo-controlled . ARM B: basimglurant 1.5 mg proof-of-concept study in multiple dose study in adult and . ARM C: matching placebo individuals with Autism pediatric patients Spectrum Disorder (ASD)

Primary . Safety and efficacy . Safety and tolerability . Efficacy - Montgomery Asberg endpoint Depression Rating Scale

Status . FPI Q3 2013 . FPI Q4 2014 . Study completed . Data in-house under review . Data presented at ECNP and ACNP 2014

Collaborator PTC Therapeutics/ SMA Foundation

ECNP=European College of Neuropsychopharmacology; ACNP=American College of Neuropsychopharmacology 116 Neuroscience development programmes

Sembragiline Anti-aSynuclein MAb Tau Molecule (MAO-B inhibitor, RG1577, (RG7935, PRX002) (RG7345) EVT-302)

Indication Parkinson’s disease Alzheimer’s Disease Alzheimer’s disease

Phase IIb Phase Phase I Phase I Phase I MAyflOwer RoAD

# of patients N=40 N=64 N=495 N=48

Design . Double-blind, placebo- . Double-blind, placebo- . 52-week oral treatment . Randomized, double-blind, controlled, single ascending controlled, multiple ascending . ARM A: RG1577 (dose 1) placebo-controlled, single dose study of RG7935 in dose study of RG7935 in . ARM B: RG1577 (dose 2) ascending dose study of healthy subjects patients with Parkinson’s . ARM C: placebo RG7345 in healthy volunteers disease

Primary . Safety, tolerability and PK . Safety and tolerability . Changes in ADAS-Cog at 52 . Safety endpoint weeks

Status . Study completed Q1 2015 . FPI Q3 2014 . Recruitment completed Q1 . FPI Q1 2015 2014

Collaborator Prothena Evotec

117 Infectious diseases development programmes

HBV therapeutic vaccine TLR7 agonist LptD antibiotic Molecule (RG7944 INO-1800 and INO- (RG7795) (RG7929) 9112))

Pseudomonas infections Indication Chronic hepatitis B Infectious diseases (including MDR strains)

Phase Phase II Phase II Phase I

# of patients N=40 N=~50 N=77

Design . Various doses of RG7795 . PK and monotherapy . INO-1800, alone or in vs. placebo studies in patients combination with INO- ongoing, 3-Phase studies 9112

Primary . Safety, efficacy . Safety, PK/PD . Safety, tolerability and endpoint immunogenicity

Status . Expect FPI Q2 2015 . FPI Q4 2013 . Expect FPI Q2 2015 . QIDP and fast track designation granted Q2 2014

Collaborator Polyphor Inovio

QIDP=Qualified Infectious Disease Product designation 118 Infectious diseases development programmes

DBO Beta lactamase NME Molecule inhibitor (RG7689) (RG6080)

Indication Infectious diseases Infectious diseases

Phase Phase I Phase I

# of patients N=77 N=40

Design . Double-blind, randomized, . Randomized, double-blind, placebo-controlled, single- placebo-controlled, single- ascending dose (SAD) and ascending dose study in multiple-ascending dose healthy volunteers (MAD) study in healthy volunteers

Primary . Safety, PK/PD . Safety, PK endpoint

Status . FPI Q4 2014 . Study completed

Collaborator Meiji and Fedora

QIDP=Qualified Infectious Disease Product designation 119 Metabolic, ophthalmology and immunology development programmes

Aldosterone synthase GLP-1/GIP dual agonist Anti-VEGF/Ang2 NME Molecule inhibitor (MAR709, RG7697) (RG7716) (RG7625) (RG7641)

Wet age-related macular Indication Type 2 diabetes Metabolic diseases Autoimmune diseases degeneration

Phase/study Phase II Phase I Phase I Phase I

# of N=105 N=96 N=12 N=16 patients

Design . ARM A: RG7697 SC . ARM A: RG7641 single Patient study . Single ascending dose of . AMR B: Liraglutide dose . Single ascending and RG7625 in healthy . ARM C: Placebo . ARM B: Placebo multiple dose of RG7716 volunteers

Primary . HbA1c . Safety . Safety and PK . Safety, PK, PD Endpoint

Status . FPI Q3 2014 . Recruitment completed . Enrollment completed . FPI Q4 2014 Q2 2014 Q4 2014

120 Pipeline summary

Marketed products additional indications

Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development)

Roche Group Q1 2015 results

Diagnostics

Foreign exchange rate information 121 Oncology development programmes Monoclonal antibodies

Duligotuzumab Anti-OX40 Molecule (Anti-HER3 EGFR DAF MAb, (RG7888, MOXR0916) RG7597)

Locally advanced or metastatic Indication Solid tumors Solid tumors tumors with mutant KRAS

Phase/study Phase I Phase I Phase I

# of patients N=50 N=400 N=360

Design . Dose finding of duligotuzumab . MOXR0916 dose escalation and . MOXR0916 plus RG7446 (anti- plus cobimetinib1 expansion study PDL1) dose escalation and expansion

Primary . Safety . Safety . Safety endpoint

Status . FPI Q4 2013 . FPI Q3 2014 . Expect FPI Q2 2015

122 Oncology development programmes Antibody drug conjugates

Anti-STEAP1 ADC NME ADC NME ADC Molecule (RG7450) (RG7882) (RG7841)

Pt. resistant ovarian cancer or Indication Prostate cancer Refractory solid tumors unresectable pancreatic cancer

Phase Phase I Phase I Phase I

# of patients N=93 N=95 N=115

Design . Dose escalation and expansion study . Dose escalation study . Dose escalation study

Primary endpoint . Safety . Safety/PK . Safety

Status . Dose escalation study: enrollment . FPI Q2 2014 . FPI Q2 2014 completed Q1 2014 . Expansion study: FPI Q3 2014 . Data presented at ASCO 2013-2014 and AACR 2014

Collaborator Seattle Genetics Seattle Genetics and Agensys

ASCO=American Society of Clinical Oncology; AACR=American Association for Cancer Research 123 Oncology development programmes Antibody drug conjugates (continued)

Lifastuzumab vedotin Molecule (anti-NaPi2b ADC, RG7599)

Platinum-sensitive ovarian cancer Indication NSCLC and ovarian cancer Platinum-resistant ovarian cancer and NSCLC

Phase II Phase Phase I Phase Ib HERAEA

# of patients N=96 N=54 N=92

Design . Dose escalation study . Dose escalation of RG7599 in . ARM A: RG7599 combination with carboplatin, with . ARM B: Pegylated liposomal or without Avastin doxorubicin

Primary . Safety . Safety, PK . Progression-free survival endpoint

Status . FPI Q2 2011 . FPI Q4 2013 . Recruitment completed Q1 2015 . Data presented at ASCO 2014

Collaborator Seattle Genetics

ASCO=American Society of Clinical Oncology 124 Oncology development programmes Small molecules

Ipatasertib Molecule (AKT inhibitor, RG7440, GDC-0068)

1L metastatic gastric or 2L castration-resistant Indication gastroesophageal junction 1L triple-negative breast cancer prostate cancer adenocarcinoma Phase II Phase II Phase II Phase A.MARTIN JAGUAR LOTUS # of patients N=262 N=153 N=120

Design . ARM A: ipatasertib (400mg) + . ARM A: ipatasertib + mFOLFOX6 . ARM A: ipatasertib + paclitaxel abiraterone . ARM B: placebo + mFOLFOX6 . ARM B: placebo + paclitaxel . ARM B: ipatasertib (200mg) + abiraterone . ARM C: placebo + abiraterone

Primary . Progression-free survival . Progression-free survival . Progression-free survival endpoint

Status . Enrollment completed Q4 2014 . Enrollment completed Q4 2014 . FPI Q3 2014

Collaborator Array BioPharma

mFOLFOX6=modified FOLFOX (Folinic acid, Fluorouracil, Oxaliplatin) 125 Oncology development programmes Small molecules (continued)

Ipatasertib Molecule (AKT inhibitor, RG7440, GDC-0068)

Indication Solid tumors Neoadjuvant TNBC

Phase II Phase Phase Ib FAIRLANE # of patients N=120 N=150

Design . Dose escalation with: . ARM A: ipatasertib + paclitaxel . ARM A: docetaxel . ARM B: placebo + paclitaxel . ARM B: fuoropyrimidine plus oxaliplatin . ARM C: paclitaxel . ARM D: enzalutamide

Primary . Safety . Pathalogic Complete Response endpoint

Status . FPI Q3 2011 . FPI Q1 2015 . Data presented at ESMO and SABCS 2014

Collaborator Array BioPharma

ESMO=European Society for Medical Oncology; SABCS=San Antonio Breast Cancer Symposium 126 Oncology development programmes Small molecules (continued)

Indoleamine 2, 3- dioxygenase (IDO) ChK1 inhibitor ERK inhibitor Molecule Inhibitor (RG7741,GDC-0575) (RG7842, GDC-0994) (GDC-0919, NLG919)

Indication Solid tumors Solid tumors or lymphoma Solid tumors

Phase Phase I Phase I Phase I

# of patients N=36 N=170 N=78

Design . Dose escalation study . Stage 1: Dose escalation . Stage 1: Dose escalation . Stage 2: Cohort expansion . Stage 2: Cohort expansion

Primary . Safety . Safety/PK . Safety, MTD, PK endpoint

Status . FPI Q1 2014 . FPI Q2 2012 . FPI Q2 2013 Collaborator NewLink Genetics Array BioPharma

127 Oncology development programmes Small molecules (continued)

Selective estrogen receptor degrader Selective estrogen receptor degrader Molecule (SERD) (SERD(2)) (RG6046, GDC-0810/ARN-810) (RG6047, GDC-0927/SRN-927)

Indication Metastatic ER+ HER2- breast cancer Metastatic ER+ HER2- breast cancer

Phase Phase I/IIa Phase I

# of patients N=141 N=90

Design . Phase I: dose escalation . Dose escalation study . Phase IIa: dose expansion

Primary . Safety, PK, MTD . Safety endpoint

Status . FPI Q4 2014 . FPI Q1 2015 . Initial data presented at SABCS 2014 and AACR 2015

Collaborator Seragon acquisition

SABCS=San Antonio Breast Cancer Symposium; AACR=American Association for Cancer Research 128 Neuroscience development programmes

Crenezumab Molecule (Anti-Aβ, RG7412)

Indication Alzheimer’s Disease

Phase II Phase II Phase/study ABBY BLAZE Cognition study Biomarker study

# of patients N=446 N=91

Design . ARM A: crenezumab SC . ARM A: crenezumab SC . ARM B: crenezumab IV . ARM B: crenezumab IV . ARM C: placebo . ARM C: placebo

Primary endpoint . Change in cognition (ADAS-cog) and Clinical . Change in brain amyloid load from baseline to Dementia Rating, Sum of Boxes (CDR-SOB) week 69 score from baseline to week 73

Status . enrollment completed Q3 2012 . enrollment completed Q3 2012 . Positive trend in cognition was observed in ARM . Cognition data presented at AAIC 2014 B for people with milder disease . Exploratory amyloid PET analysis suggests . Data presented at AAIC 2014 reduced amyloid accumulation in ARM B . Biomarker data presented at CTAD 2014 Collaborator AC Immune

AAIC=Alzheimer’s Association International Conference; CTAD=Clinical Trials on Alzheimer’s Disease 129 Neuroscience development programmes

Crenezumab Nav1.7 Molecule (Anti-Aβ, RG7412) (RG7893, GDC-0276)

Mild to Moderate Alzheimer's Alzheimer’s Prevention Initiative Indication Pain disease (API) Colombia

Phase II Phase/study Phase I Phase I Cognition study

# of patients N=24 N=300 N=74

Design . ARM A: crenezumab dose level 1 . ARM A: 100 carriers receive . Phase 1, randomized, placebo- . ARM B: placebo dose level 1 crenezumab SC controlled, double blinded study to . ARM C: crenezumab dose level 2 . ARM B: 100 carriers receive placebo determine safety, tolerability, and . ARM D: placebo dose level 2 . ARM C: 100 non-carriers receive pharmacokinetics in healthy placebo volunteers

Primary . Safety (incidence and nature of MRI . Change on Alzheimer's Prevention . Safety, tolerability, and endpoint safety findings) Initiative (API) Composite Cognitive pharmacokinetics of single and Test total score multiple doses

Status . FPI Q1 2015 . FPI Q4 2013 . FPI Q3 2014

Collaborator AC Immune and Banner Alzheimer’s AC Immune Xenon Pharmaceuticals Inc. Institute

130 Immunology and infectious diseases development programmes

NME Anti-Flu A Molecule (RG7880) (RG7745)

Indication Inflammatory diseases Influenza

Phase/study Phase I Phase IIb

# of patients N=74 N~300 Design • Healthy volunteer study Hospitalized patients requiring oxygen with severe influenza A . ARM A: RG7745 + Tamiflu . ARM B: placebo + Tamiflu

Primary • Safety and tolerability . Safety and efficacy (time to endpoint normalization of respiratory function)

Status • FPI Q4 2014 . FPI Q1 2015

131 Pipeline summary

Marketed products additional indications

Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development)

Roche Group Q1 2015 results

Diagnostics

Foreign exchange rate information 132 Geographical sales split by divisions and Group*

CHFm Q1 2015 Q1 2014 % change CER Pharmaceuticals Division 9,040 9,322 +4 United States 3,873 4,392 +6 Europe 2,425 2,178 +1 Japan 845 763 -2 International 1,897 1,989 +9 Diagnostics Division 2,456 2,511 +6 United States 558 616 +3 Europe 1,028 946 +3 Japan 111 91 -10 International 759 858 +14 Group 11,496 11,833 +5 United States 4,431 5,008 +6 Europe 3,453 3,124 +1 Japan 956 854 -3 International 2,656 2,847 +10 133 * Geographical sales split shown here does not represent operational organisation; CER=Constant Exchange Rates Pharma Division sales Q1 2015 (vs. 2014) Top 20 products

Global US Europe Japan International CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER MabThera/Rituxan 1,744 5 937 10 452 1 52 1 303 2 Herceptin 1,652 12 598 18 508 0 60 -7 486 23 Avastin 1,619 6 761 6 456 3 167 4 235 11 Lucentis 394 -9 394 -9 ------Tamiflu 376 6 284 49 11 -83 54 -2 27 -20 Actemra/RoActemra 334 27 124 35 110 24 49 1 51 55 Perjeta 322 82 187 60 89 140 18 12 28 222 Tarceva 295 -3 154 2 58 -15 20 -12 63 1 Xolair 281 28 281 28 ------Activase/TNKase 221 15 210 16 - - - - 11 -2 CellCept 197 -7 43 -17 44 -10 12 -3 98 -2 Kadcyla 179 80 78 -1 73 229 12 - 16 333 Pegasys 168 -39 12 -82 31 -55 6 -50 119 -8 Pulmozyme 146 4 102 4 29 2 - - 15 9 Xeloda 136 -53 15 -89 13 -59 20 -8 88 -17 Mircera 114 17 - - 22 -3 40 -14 52 99 Valcyte/Cymevene 100 -41 24 -76 40 -2 - - 36 4 NeoRec./Epogin 93 -10 - - 39 -10 11 -24 43 -6 Esbriet 88 - 50 - 32 - - - 6 - Rocephin 79 18 - - 15 14 7 -9 57 25

CER=Constant Exchange Rates 134 Pharma Division sales Q1 2015 (vs. 2014) Recently launched products

Global US Europe Japan International CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER Zelboraf 55 -25 12 -40 33 -28 - - 10 18 Erivedge 33 36 23 52 8 -3 - - 2 165 Gazyva 26 223 17 105 4 * - - 5 -

CER=Constant Exchange Rates 135 * over +500%

Pharma Division CER sales growth1 in % Global top 20 products

Q1/14 Q2/14 Q3/14 Q4/14 Q1/15 MabThera/Rituxan 3 5 1 -1 5 Herceptin 3 9 9 7 12 Avastin 9 4 6 7 6 Lucentis 8 4 2 -5 -9 Tamiflu 9 -36 121 129 6 Actemra/RoActemra 23 21 28 20 27 Perjeta 274 277 227 103 82 Tarceva -5 3 0 -2 -3 Xolair 15 22 33 29 28 Activase/TNKase -1 26 19 5 15 CellCept -1 -11 0 -4 -7 Kadcyla 474 105 103 110 80 Pegasys -19 -10 -22 -29 -39 Pulmozyme 3 8 13 4 4 Xeloda -19 -50 -61 -56 -53 Mircera 21 2 -1 0 17 Valcyte/Cymevene 12 12 19 -9 -41 NeoRec./Epogin -9 -8 -12 -1 -10 Esbriet - - - - - Rocephin 7 -1 18 14 18 CER=Constant Exchange Rates 136 1 Q1-Q4/14 vs. Q1-Q4/13; Q1/15 vs. Q1/14 Pharma Division CER sales growth1 in % Top 20 products by region US Europe Japan International Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 MabThera/Rituxan 8 -4 5 10 8 4 7 1 -17 5 -4 1 -2 9 -17 2 Herceptin 17 10 17 18 4 4 2 0 -12 5 -7 -7 12 14 6 23 Avastin 6 3 7 6 2 1 3 3 -5 13 5 4 9 15 16 11 Lucentis 4 2 -5 -9 ------Tamiflu 22 155 127 49 -71 49 -93 -83 -74 238 190 -2 -44 37 350 -20 Actemra/RoActemra 30 39 31 35 20 25 22 24 5 21 11 1 28 21 6 55 Perjeta 205 202 86 60 287 228 171 140 - 375 32 12 * 341 177 222 Tarceva 16 11 9 2 -12 -9 -9 -15 6 7 -6 -12 -9 -13 -13 1 Xolair 22 33 29 28 ------Activase/TNKase 27 18 4 16 ------19 27 12 -2 CellCept -6 16 -18 -17 -5 -6 -11 -10 -14 -12 -13 -3 -16 -3 13 -2 Kadcyla 16 3 -7 -1 * * * 229 - - - - * * * 333 Pegasys -14 -51 -49 -82 -32 -38 -46 -55 45 48 -1 -50 3 -8 -17 -8 Pulmozyme 10 20 9 4 -1 -5 -2 2 - - - - 9 10 -1 9 Xeloda -80 -93 -92 -89 -71 -76 -77 -59 -23 -6 -8 -8 -2 -19 -10 -17 Mircera - - - - -1 -3 -8 -3 -12 -2 -11 -14 32 1 30 99 Valcyte/Cymevene 8 21 -13 -76 10 22 -9 -2 - - - - 24 12 -1 4 NeoRec./Epogin - - - - -10 -15 -10 -10 -45 -38 -39 -24 12 3 28 -6 Esbriet ------Rocephin - - - - -8 17 7 14 -19 -16 -15 -9 5 27 30 25 CER=Constant Exchange Rates * over 500% 137 1 Q2-Q4/14 vs. Q2-Q4/13; Q1/15 vs. Q1/14 CER sales growth (%) Quarterly development

2014 vs. 2013 2015 vs. 2014 Q1 Q2 Q3 Q4 Q1

Pharmaceuticals Division 4 4 4 5 4 United States 3 8 4 10 6 Europe 5 1 1 4 1 Japan 19 -4 8 5 -2 International 1 3 6 0 9

Diagnostics Division 7 5 7 7 6 Roche Group 5 4 5 6 5

CER=Constant Exchange Rates 138 Q1 2015: Oncology

Q1 2015 sales of CHF 5.818bn US 2015 vs. 2014 • HER2 franchise (driven by Herceptin and CHFbn CER growth PERJETA), and Avastin (+6%) driving +6% growth and performance 7.0 Europe 6.0 +4% • Growth mainly driven by HER2 franchise 5.0 +10% (with strong uptake of PERJETA & Kadcyla), and Avastin (+3%) 4.0 +5% International 3.0 • Continued strong growth for Herceptin 2.0 (+23%) and Avastin (+11%) +6% 1.0 Japan 0.0 • Growth driven largely by Perjeta (+12%) Q1 13 Q1 14 Q1 15 and Avastin (+4%) US Europe International Japan

CER=Constant Exchange Rates 139 MabThera/Rituxan

Global sales CER growth Regional sales CER growth CHFbn +5% US +10% 2.0

Europe +1% 1.5

Japan +1% 1.0

International +2% 0.5

0.0 Q1 11 Q1 12 Q1 13 Q1 14 Q1 15

Q1 2015 sales of CHF 1.744bn • Immunology sales (RA and GPA/MPA) grew +11% • Oncology sales grew +4% driven by all regions in various indications • International: Growth driven by several regions, especially Latin America

CER=Constant Exchange Rates 140 Avastin

Global sales CER growth Regional sales CER growth CHFbn +6% US +6% 2.0

1.5 Europe +3%

1.0 Japan +4%

0.5 International +11%

0.0 Q1 11 Q1 12 Q1 13 Q1 14 Q1 15

• Q1 2015 sales of CHF 1.619b • Europe: Growth driven by further uptake in ovarian and breast cancer (IMELDA study) • US: Sales largely driven by cervical, ovarian and lung cancer • Japan: Growth driven by all indications • International: Strong growth driven by all regions

CER=Constant Exchange Rates 141 Herceptin

Global sales CER growth Regional sales CER growth CHFbn +12% US +18% 2.0

1.5 Europe 0%

1.0 Japan -7%

0.5 International +23%

0.0 Q1 11 Q1 12 Q1 13 Q1 14 Q1 15

Q1 2015 sales of CHF 1.652bn • US: Strong growth in 1L mBC due to longer treatment times; some phasing issues contributing • Europe: Stable sales; conversion rate to subcutaneous formulation progressing well • International: Strong growth in Latin America driven by access in public markets, as well as Asia, particularly from the patient assistance program in China

CER=Constant Exchange Rates 142 Xeloda

Global sales CER growth Regional sales CER growth CHFbn -53% US -89% 0.4 Europe -59%

0.3 Japan -8%

0.2 International -17%

0.1

0.0 Q1 11 Q1 12 Q1 13 Q1 14 Q1 15

• Q1 2015 sales of CHF 0.136bn • Overall impact due to loss of exclusivity (LoE): – US: LoE in February 2014 – Europe: LoE in December 2013

CER=Constant Exchange Rates 143 Tarceva

Global sales CER growth Regional sales CER growth CHFbn -3% US +2% 0.4 Europe -15% 0.3 Japan -12%

0.2 International +1% 0.1

0.0 Q1 11 Q1 12 Q1 13 Q1 14 Q1 15

Q1 2015 sales of CHF 0.295bn • Overall growth in 1L EGFR Mut+ NSCLC compensates for decline in 2/3L EGFR WT NSCLC • Europe: Decrease largely due to Abraxane launched in 1L pancreatic cancer in Germany • International: Local competition in China

CER=Constant Exchange Rates 144 HER2 Franchise (Herceptin, Perjeta, Kadcyla)

Global sales CER growth Regional sales CER growth CHFbn +23% US +23% 2.5

2.0 Europe +18%

1.5

1.0 Japan +12%

0.5 International +30%

0.0 Q1 11 Q1 12 Q1 13 Q1 14 Q1 15

Q1 2015 sales of CHF 2.153bn • Strong growth driven by continued uptake of PERJETA in 1/2L mBC and in the neoadjuvant setting, (particularly US), as well as by Kadcyla in 2L mBC • Continued strong growth in Herceptin benefiting from higher volumes / prolonged treatment times CER=Constant Exchange Rates 145 Perjeta

Global sales CER growth Regional sales CER growth CHFbn +82% US +60% 0.4

Europe +140% 0.3

0.2 Japan +12% International +222% 0.1

0.0 Q1 11 Q1 12 Q1 13 Q1 14 Q1 15

Q1 2015 sales of CHF 0.322bn • Perjeta sales grew in all regions with strong uptake in the US, Germany and France – Approved in all major markets for 1L mBC – Also benefitting from impressive OS data of CLEOPATRA study (US label update in Q1 `15) – Neoadjuvant Indication approved in US and 17 other markets CER=Constant Exchange Rates 146 Q1 2015: Immunology

Q1 2015 sales of CHF 1.410bn

2015 vs. 2014 Actemra (+27%) CHFbn CER growth • EU: +24% supported by strong 1L +20% monotherapy patient share uptake and SC 1.6 launch 1.4 -2% • US: +35% driven by continued SC uptake 1.2 +12% • International: +55% driven by all regions especially LATAM 1.0 +19% Xolair (+28%) 0.8 • Growth in Asthma 0.6 • Growth in Chronic Idiopathic Urticaria 0.4 +27% (CIU) post FDA approval in Q1 ‘14 0.2 MabThera/Rituxan (+11%)

0.0 • Continues to grow in rheumatoid arthritis Q1 13 Q1 14 Q1 15 and vasculitis (GPA and MPA)

US Europe International Japan

CER=Constant Exchange Rates 147 Tamiflu quarterly sales 2011 - 2015 Retail and Governments/Corporations

Retail 600 Governments & Corporations

500

400

300 496 277 376 200 288 302 233 214 100 177 70 12 26 44 32 67 7 45 46 15 17 0 31 33 19 3 -6 10 8 5 1 2 7 11 10 11 0

-100 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 11 11 11 11 12 12 12 12 13 13 13 13 14 14 14 14 15

148 March 2015: Debt maturity profile 77% of Genentech related debt repaid

CHF bn 4 GBP CHF EUR USD 3

2

1

0 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2035 2039 2044

Of the CHF 48 bn bonds and notes issued to finance the Genentech transaction, cumulative CHF 37 bn have been repaid as of March 31, 2015*

Nominal values @ actual FX rates; *Original net proceeds in CHF 149

Pipeline summary

Marketed products additional indications

Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development)

Roche Group Q1 2015 results

Diagnostics

Foreign exchange rate information 150 Diagnostics Division CER growth By Region and Business Area (vs. 2014)

Global North America EMEA¹ RoW % CER % CER % CER % CER CHFm growth CHFm growth CHFm growth CHFm growth

Professional Diagnostics 1,425 6 323 4 605 3 497 12 Diabetes Care 507 1 94 -11 304 0 109 17 Molecular Diagnostics 401 10 160 17 158 13 83 -6 Tissue Diagnostics 178 14 105 11 48 18 25 19

Diagnostics Division 2,511 6 682 5 1,115 4 714 10

CER=Constant Exchange Rates 151 ¹ Europe, Middle East and Africa Diagnostics Division quarterly sales and CER growth1

Q4 13 Q1 14 Q2 14 Q3 14 Q4 14 Q1 15 CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER

Professional 1,521 10 1,392 9 1,512 8 1,493 8 1,648 8 1,425 6 Diagnostics

Diabetes 678 -4 538 5 602 -4 581 4 671 1 507 1 Care

Molecular 416 3 370 4 392 3 403 8 448 7 401 10 Diagnostics

Tissue 184 10 156 4 178 14 175 13 207 10 178 14 Diagnostics

Dia Division 2,799 5 2,456 7 2,684 5 2,652 7 2,974 7 2,511 6

CER=Constant Exchange Rates 152 ¹ versus same period of prior year Q1 2015: Diagnostics Division sales Growth driven by Asia Pacific

CHF 2,511 m CER sales growth

682 North America 27% Diagnostics Division 6%

EMEA¹ 4% Asia Pacific 19% North 463 America 5%

Asia Pacific 16%

Latin Latin America 6% 11% 1,115 159 America 92 Japan 4% Japan -10% EMEA1 44%

CER=Constant Exchange Rates 153 ¹ Europe, Middle East and Africa Q1 2015: Diagnostics Division sales Growth driven by Professional Diagnostics

CHF 2,511 m CER sales growth

Dia 507 Diabetes Care 20% Division 6%

Professional Diagnostics 6% Molecular Diagnostics 16% 401 Diabetes Care 1%

1,425 Molecular Diagnostics 10% 178 Tissue Diagnostics 7%

Tissue Diagnostics 14% Professional Diagnostics 57%

CER=Constant Exchange Rates 154 Professional Diagnostics Strong growth driven by Immunodiagnostics

2015 vs. 2014 CHFbn CER growth

1.5 +6% +1% 1.2 +4%

0.9 +1%

0.6

0.3 +11%

0.0 Q1 13 Q1 14 Q1 15 Immunodiagnostics Clinical Chemistry POC products Other

CER=Constant Exchange Rates 155 Diabetes Care Adapting to a challenging market environment

2015 vs. 2014 CHFbn CER growth

0.6 +1%

0.5 +11%

0.4

0.3 0% 0.2

0.1

0.0 Q1 13 Q1 14 Q1 15 Blood Glucose Monitoring Other

CER=Constant Exchange Rates 156 Molecular Diagnostics Growth mainly driven by Virology

2015 vs. 2014 CHFbn CER growth +10%

0.4 +33%

0.3 +17% -4% 0.2 +5%

0.1 +10%

0.0 Q1 13 Q1 14 Q1 15 Other HPV & Microbiology Blood Screening Biochem Reag & qPCR & NAP Systems Virology CER=Constant Exchange Rates 157 Tissue Diagnostics Strong growth in North America and EMEA¹

2015 vs. 2014 CHFbn CER growth

0.2 +14% -19% -8% +75%

0.1

+13%

0.0 Q1 13 Q1 14 Q1 15 Advanced Staining Companion Dia Primary Staining Digit Path&Workflow CER=Constant Exchange Rates 158 ¹ Europe, Middle East and Africa 2015: Key planned product launches Professional Diagnostics

Product Description Region

cobas c 513 dedicated HbA1C analyzer EU

cobas t 411 core lab coagulation analyzer EU

Cobas 8100 V2 integrated pre- and post-analytical solution WW  CoaguChek Pro II professional system for PT and aPTT testing EU

HTLV human T-lymphotropic virus diagnostics test EU

Cobas h 232 Point of Care test version of Elecsys cTNT-hs EU Troponin T

Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors 159 2015: Key planned product launches Molecular Diagnostics

Product Description Region

cobas® 6800/8800 medium to high volume automated real-time PCR US

cobas® 6800/8800 multiplex bloodscreening test US MPX cobas® 6800/8800 quantitative HBV viral load test EU HBV  cobas® 4800 HIV-1 quantitative HIV viral load test EU cobas® 4800 HCV quantitative HCV viral load test cobas® 4800 HBV quantitative HBV viral load test

cobas® EGFR Test v2 detection of EGFR in plasma EU

cobas® Liat POC detection US Influenza A/B + RSV

Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors 160 2015: Key planned product launches Tissue Diagnostics

Product Description Region

VENTANA HE 600 automated H&E staining platform WW

Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors 161 2015: Key planned product launches Diabetes Care

Product Description Region

Accu-Chek Active next-gen. bG meter, no coding of test strips WW no-code Accu-Chek Connect bG meter with connectivity to smartphones, mobile US applications and cloud

Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors 162 Pipeline summary

Marketed products additional indications

Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development)

Roche Group Q1 2015 results

Diagnostics

Foreign exchange rate information 163 CHF / USD

Monthly averages 0.99 0.97 2015 0.95 0.93 0.91 2014 0.89 0.87 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Year-To-Date averages 0.99 0.97 2015 0.95 0.93 +7% 0.91 2014 0.89 0.87 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

164 CHF / USD

0.99 monthly avg 2015

0.97 monthly avg 2014 Q1 2015 avg 0.95

+4% 0.93 avg full year 2014 0.91

0.89

0.87 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

165 CHF / EUR

Monthly averages 1.25

1.20 2014 1.15 2015 1.10

1.05 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Year-To-Date averages 1.25

1.20 2014 1.15 -12% 2015 1.10

1.05 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

166 CHF / EUR

1.25

avg full year 2014

1.20 monthly avg 2014

1.15 -11%

1.10 Q1 2015 avg monthly avg 2015 1.05 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

167 Average exchange rates

Q1 15 Q1 14 Q1 15 vs. Q1 14

USD 0.95 0.89 7%

EUR 1.08 1.22 -12%

JPY 0.80 0.87 -8%

-15% -10% -5% 0% 5% 10%

168 Exchange rate impact on sales growth Negative impact from EUR and JPY more than offsetting positive impact from USD Development of average exchange rates versus prior year period CHF / EUR -12.1% CHF / USD +6.8% CHF / JPY -7.8%

Difference in CHF / CER -1.9%p growth

4.8%

Sales 2.9% growth CER CHF 2015 growth growth vs. 2014

Q1 HY YTD 9 FY CER=Constant Exchange Rates 169 Doing now what patients need next